Dexcom (DXCM) 10-K risk factor changes: FY2023 vs FY2022
The 2023-12-31 10-K against the 2022-12-31 one, compared heading by heading and sentence by sentence.
Item 1A163 rewritten81 added129 removed906 unchanged
All filing items918 rewritten450 added550 removed2,346 unchanged
Sentence counts leave out repeated page headers and footers. 5 of those lines differ and are listed apart under each item.
Summary
counted, not written
- Item 1A lists 77 risk factor headings: 4 new, 2 reworded and 71 unchanged since FY2022. 5 headings from FY2022 no longer appear.
- Sentence by sentence, 450 added, 550 removed, 918 rewritten and 2,346 unchanged across 19 items that differ.
- Not counted above: 5 repeated page header or footer lines also differ. They are listed apart under each item.
- New this year: Item 1C. CYBERSECURITY.
New Item 1A headings (4)
- We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.
- The capped call transactions we entered into in connection with the pricing of the 2028 Notes may affect the value of our 2028 Notes and common stock.
- The warrants related to the 2023 Notes and our common stock.
- We are subject to counterparty risk with respect to the 2028 Capped Calls.
Removed Item 1A headings (5)
- causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.”
- The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
- Valuation of share-based payments, which we are required to perform for purposes of recording compensation expense under authoritative guidance for share-based payment, involves assumptions that are subject to change and difficult to predict.
- The convertible note hedge and warrant transactions may affect the value of the 2023 Notes and our common stock.
- We are subject to counterparty risk with respect to the 2023 Note Hedge transactions.
Reworded Item 1A headings (2)
- We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in
[removed: future]revenue. - Failure to protect our information technology infrastructure against
[removed: cyber-based attacks,][added: cyberattacks,] network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.
A heading is new when no FY2022 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
24 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2023; struck-through words were in FY2022. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. RISK FACTORS
163 rewritten, 81 added, 129 removed, 906 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
Before making a decision to invest in, hold or sell our common stock, stockholders and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained in or incorporated by reference into this Annual Report on Form 10-K, as well as the other information we file with the [removed: Securities] [added: SEC, including our subsequent reports on Forms 10-Q] and [removed: Exchange Commission.][added: 8-K.]
Refer to our disclaimer regarding forward-looking statements at the beginning of [removed: Management’s Discussion and Analysis of Financial Condition and Results of Operations in] [added: Part I,] Item [removed: 7] [added: 1] of this Annual [removed: Report.*][added: Report on Form 10-K.*]
We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to pricing pressure from managed care organizations and other third-party payors, increased market power of [removed: our] payors, and increased competition among suppliers, including manufacturing services providers, as the medical device industry consolidates.
We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in [removed: future] revenue.
We expect that [removed: the] [added: these] continuing cost reduction and containment measures may reduce the cost or utilization of [removed: health care] [added: our] products and could lead to patients being unable to obtain approval for coverage or payment from these third-party payors or to costs being shifted to patients for our products.
Additionally, as a result of the [removed: ongoing COVID-19 pandemic, and] economic slowdown, some customers have lost access and others may lose access to their private health insurance plan if they lose their job, and an impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our [removed: customer.][added: customers.]
As most of our customers [added: currently] rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products, our customers may lose coverage or reimbursement for our products, which may harm our business and results of operations.
To the extent these cost containment efforts are not offset by greater patient access to our products, our [removed: future] revenue may be reduced and our business may be harmed.
Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual [removed: coverage,] [added: coverage] with third-party [removed: payors] [added: payors,] and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products.
Therefore, Medicare reimbursement for our CGM devices is subject to various coverage conditions [removed: and often requires a patient-specific coverage analysis.]
[removed: A] [added: We face a] number of regulatory and commercial hurdles [removed: remain] relating to wide-scale sales where a government or commercial third-party payor provides reimbursement, including sales to Medicare beneficiaries.
As of December 31, [removed: 2022,] [added: 2023,] the eight largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices.
Among other things, people with diabetes without insurance that covers our products bear the [added: entire] financial cost of [removed: them.][added: using our products.]
CMS has [removed: proposed new draft] [added: adopted] coverage guidelines for CGMs, which [removed: if implemented, would] [added: could] have a favorable impact on us.
[removed: Currently,] [added: Previously,] Medicare coverage for CGM [removed: is] [added: was] only available to Medicare patients who take at least three doses of insulin a day, limiting CGM reimbursement for Medicare beneficiaries with intensive Type 1 and 2 diabetes.
Further, the LCD [removed: would] also [removed: allow] [added: allows] coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia.
We are unable to predict what effect the current or any future healthcare reform will [added: have on our business, or the effect these matters will have on our customers.]
Accordingly, unless government and other third-party payors provide adequate coverage and reimbursement for our current CGM [removed: systems,] [added: systems or any future products we may develop,] people without coverage who have diabetes may not use our products.
Furthermore, payors are increasingly basing reimbursement rates on factors such as prior approvals and the effectiveness of the product, clinical outcomes associated with the product, and any factors that [removed: negatively impact the effectiveness or clinical outcomes (or cause a perception of any such negative impact), such as the results of a clinical trial, a product defect, or a product recall, which could negatively impact the reimbursement rate.]
In [removed: some] [added: many] foreign markets, pricing and profitability of medical devices are subject to government control.
In order to address the anticipated needs of our customers, pursue new markets for our existing [added: products and any new] products, and [added: to] remain competitive, we focus our research and development efforts and strategic third-party collaboration activities on the enhancement of our current CGM products, the development of next-generation products and the development of novel technologies and services.
The development of new products, or novel technologies and services and the enhancement of our current CGM products (including seeking and potentially obtaining new indications for use), requires significant investment in research and development, intellectual property protection, clinical trials, regulatory approvals and [added: in obtaining] third party reimbursement.
Failing to timely launch our [added: new] products [added: and any enhancements to our existing products] may cause them to become obsolete and materially and adversely affect our business and financial position.
Even if our development and clinical trial efforts appear successful to us and our regulatory submission appears satisfactory to us, the FDA [added: or comparable international regulator] may disagree and may decide not to grant marketing authorization for the products or may require additional product testing or clinical trials or other data to be developed and submitted before approving the products, which would result in product launch delays and additional expense.
Even if a product receives marketing authorization from the [removed: FDA,] [added: FDA or comparable international regulator,] it may not be accepted in the marketplace by [removed: physicians] [added: health care professionals] and people with diabetes.
In the ordinary course of our business we enter into collaborative arrangements with third parties to expand into new markets, including with insulin device manufacturers [removed: such as Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes and The Ypsomed Group] to integrate our CGM technology into [removed: their] [added: the third parties’] insulin delivery systems.
Any factors that may limit our partners’ ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to insulin pump products, or [removed: changes in]
[added: changes in] reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.
We expect that sales of our [removed: current] CGM systems will account for substantially all of our product revenue for the foreseeable future.
- widespread market acceptance of our products by [removed: physicians] [added: health care professionals] and people with diabetes will largely depend on our ability to demonstrate their relative safety, effectiveness, reliability, cost-effectiveness and ease of use;
[removed: Physicians] [added: Health care professionals] may not recommend or prescribe our products unless and until (i) there is more long-term clinical evidence to convince them to alter their existing treatment methods, (ii) there are additional recommendations from prominent physicians that our products are effective in monitoring glucose levels, and (iii) reimbursement or insurance coverage is more widely available.
Our existing manufacturing facilities are designed to manufacture current and next-generation [removed: sensors and transmitters,] [added: CGM systems,] but may not be scaled quickly enough to permit us to manufacture one or more of our CGM systems in quantities sufficient to meet market demand.
We will need to adequately predict the market demand for our products and increase our manufacturing capacity by a significant factor over the current level to meet or exceed the anticipated market [removed: demand.][added: demand by product.]
In addition, we [removed: will] [added: may] have to modify our manufacturing design, reliability and process [removed: if and when our] [added: for] next-generation [removed: CGM technologies are] [added: products that may hereafter be] approved, cleared or otherwise authorized by the applicable regulatory body and commercialized.
Our facilities are subject to inspections by the FDA and corresponding state [added: and international] agencies on an ongoing basis, and we must comply with Good Manufacturing Practices and the FDA Quality System Regulation, as well as certain state [removed: requirements.]
We may be unable to adequately maintain, develop and expand our manufacturing process and operations or maintain compliance with FDA and state [added: and international] agency requirements, and manufacturing issues could impact our cleared and approved products.
Because of the time required to [removed: approve] [added: approve, lease,] and [removed: lease] [added: build out] a manufacturing facility, an alternate facility and/or a third-party may not be available on a timely basis to replace production capacity in the event manufacturing capacity is lost.
Additionally, the majority of our operations are conducted at facilities located in San Diego, California, Mesa, [removed: Arizona and, beginning in 2023, Penang] [added: Arizona, and] Malaysia.
However, a natural or man-made disaster, such as fire, flood, earthquake, act of terrorism, cyber-attack or other disruptive event, such as [removed: the ongoing COVID-19 pandemic or another] [added: a] public health emergency, could cause substantial delays in our operations, damage, destroy or limit our manufacturing equipment, inventory, or records and cause us to incur additional expenses.
Our manufacturers and suppliers may also experience or be impacted by equipment malfunction, environmental factors, and public health [removed: emergencies including but not limited to the ongoing COVID-19 pandemic,] [added: emergencies,] any of which could delay or impede their ability to meet our demand.
and often requires a patient-specific coverage analysis.
The Local Coverage Determination, or LCD, that CMS released in April 2023 extends Medicare CGM coverage to patients who use any insulin.
negatively impact the effectiveness or clinical outcomes (or cause a perception of any such negative impact), such as the results of a clinical trial, a product defect, or a product recall, which could negatively impact the reimbursement rate.
As we continue to expand internationally, these government controls will have an increasing effect on our business and results of operations.
Any of the above factors may have a material adverse effect on our ability to increase or maintain our revenue or otherwise have a material adverse impact on our business, financial condition, and results of operations.
- the introduction and market acceptance of new drug therapies for the treatment and management of diabetes and related conditions, including obesity;
We are also aware of the increasing use of GLP-1 products for the treatment of obesity and Type 2 diabetes.
While we believe that GLP-1s are a companion product and used in conjunction with our CGM systems, these treatments could potentially compete with our CGM systems and reduce sales of our products.
In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing.
We are also expanding our facility in Mesa, Arizona, and plan to begin construction of a new facility in Ireland to scale up manufacturing capacity.
requirements.
If we experience manufacturing difficulties or disruptions, it could result in insufficient inventory, increased costs, immediate shortages in product or component supply, and decreased sales, and our business could be harmed.
If there are regulatory delays or impediments impacting
device market.
Likewise, Abbott Diabetes Care has received FDA clearance to integrate certain versions of their Libre sensors into automated insulin delivery systems and is pursuing such integrations with third-party insulin delivery devices.
We are also aware of the increasing use of GLP-1 products for the treatment of obesity and Type 2 diabetes.
While we believe that GLP-1s are a companion product and used in conjunction with our CGM systems, these treatments could potentially compete with our CGM systems and reduce sales of our products.
We are subject to risks associated with public health issues, such as the recent COVID-19 pandemic, and other events beyond our control.
Public health issues and crises may adversely impact our operations, supply chain and logistics network if the locations where we operate, manufacture or distribute our products; where our raw materials or products are sourced, manufactured or distributed; or where our third-party distributors, suppliers and other service providers operate, are disrupted, temporarily closed or experience worker shortages for a sustained period of time.
In addition, public health issues and crises may adversely impact our customers and/or their businesses due to lockdowns, labor shortages, lost access to private health insurance plans or modified spending priorities, all of which could cause a decline in demand for our products.
These disruptions could also cause economic slowdowns or increased economic uncertainty.
Any of the forgoing could adversely affect our business, financial condition and results of operations.
For example, in 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing.
We also and plan to begin construction of a new facility in Ireland.
instances, non-U.S. persons, in conducting activities, and transacting business with or making investments in certain countries, governments, entities and individuals subject to U.S. economic sanctions.
Some of these laws include the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, the European Union’s General Data Protection Regulation, or GDPR, the UK Data Protection Act and the UK GDPR, and the California Consumer Privacy Act as amended, or CCPA, and the Washington My Health My Data Act, among others.
Penalties for failure to adequately protect personal information, notify as required, or provide timely notice vary by jurisdiction.
In the U.S., most state data breach notification laws consider violations to be unfair or deceptive trade practices and give the relevant state attorneys general (“AGs”) the authority to levy fines or bring enforcement actions.
Such AG investigations—which are often time consuming, expensive, and burdensome—may lead to a resolution agreement, whereby certain obligations are performed and reports are made to the AG for a period of time, and/or civil penalties.
Class action lawsuits against companies which experience a data breach involving personal information are also common.
Additionally, the SEC and many jurisdictions have enacted or may enact laws and regulations requiring companies to disclose or otherwise provide notifications regarding data security breaches.
For example, the SEC recently adopted cybersecurity risk management and disclosure rules, which require the disclosure of information pertaining to cybersecurity incidents and cybersecurity risk management, strategy, and governance.
We may be subject to inquiries, investigations and audits in Europe and around the world, particularly in the areas of consumer and data protection,
The HIPAA Security Rule requires covered entities, including Dexcom, and business associates to implement administrative, physical, and technical safeguards to protect the integrity, confidentiality and availability of protected health information that is electronically created, received, maintained or transmitted.
Covered entities are also required to report any unauthorized use or disclosure of protected health information that meets the definition of a breach under the Breach Notification Rule, to affected individuals, OCR and, depending on the number of affected individuals, the media for the affected market.
In addition, HIPAA requires that business associates report breaches to their covered entity customers.
We have adopted breach notification policies and procedures designed to comply with the applicable requirements set forth in HIPAA.
HIPAA establishes a federal “floor” with respect to privacy, security, and breach notification requirements and does not supersede any state laws insofar as they are broader or more stringent than HIPAA.
Numerous state and certain other federal laws protect the confidentiality of health information and other personal information, including but not limited to state medical privacy laws, state laws protecting personal information, state data breach notification laws, state genetic privacy laws, human subjects research laws and federal and state consumer protection laws.
These additional federal and state privacy and security-related laws may be more restrictive than HIPAA and could impose additional penalties.
The ongoing COVID-19 pandemic may result in increased costs for manufacturing and outsourced services while also causing additional pressure to reduce the prices for our products if a recession or depression occurs and people are unable to afford our products.
We cannot predict the ultimate impact that the ongoing COVID-19 pandemic, economic conditions, or their effects could have on our business operations, financial condition and cash flows.
The draft Local Coverage Determination (LCD), if finalized, would extend Medicare CGM coverage to patients who use insulin at least once per day.
We expect CMS to release the final coverage decision this year.
have on our business, or the effect these matters will have on our customers.
- for people with Type 2 diabetes, current reimbursement from third-party payors is generally limited to people on intensive insulin therapy;
Further, insurance coverage may not be available or successfully secured for loss of profits or business interruption relating to the COVID-19 pandemic and its impacts.
For supply risks related to the ongoing COVID-19 pandemic see our Risk Factor entitled, *“The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it*
Closure of non-essential businesses and shelter-in-place orders occurring in the U.S. and globally as a result of the ongoing COVID-19 pandemic may also adversely impact our outsourced operations.
We continue to monitor this situation closely.
Although we have enabled our sales and marketing activity to be conducted virtually and remotely, restrictions in connection with the COVID-19 outbreak may have a substantial impact on our customers and sales cycles and have impacted and/or interrupted our sales and marketing activity.
COVID-19 restrictions vary by location across the United States and other regions of the world, which may continue to limit or prohibit our sales force from having in-person interactions with healthcare professionals and people with diabetes, which may result in decreased sales of our products.
Therefore, our
The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes has been and continues to be a global pandemic.
The novel coronavirus, as well as new variants of the coronavirus have spread to most regions of the world, including the United States and Europe.
The extent to which this coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new variants of the virus and new information that may emerge concerning the virus and the actions to contain it or to mitigate the COVID-19 impact, among others.
It is especially difficult to predict the impact on the global economic markets, which have been and will continue to be highly dependent upon the actions of governments, businesses, and other enterprises in response to the pandemic, as well as the effectiveness of those actions, and vaccine availability, distribution, efficacy and adoption.
The ongoing COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we have, and may continue to experience more pronounced disruptions in our operations.
The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business.
For example, such restrictions may have a substantial impact on our customers and sales cycles.
They have impacted our sales and marketing activity including quite significantly in Europe where more restrictive health protection measures and greater reliance on in-person sales efforts at doctors’ offices create a greater impediment to our selling efforts.
Furthermore, changes in hospital or physician policies, federal, state or local regulations, prioritization of hospital or medical resources toward pandemic efforts may negatively affect the demand for our devices.
The COVID-19 pandemic has, and may continue to, put pressure on global economic conditions and overall spending for medical device products, and may cause our customers to modify spending priorities or delay or abandon purchasing decisions.
Further, if the spread of the coronavirus pandemic continues and our operations are adversely impacted, we risk a delay, default and/or nonperformance under existing agreements.
Severe respiratory symptoms, infections and deaths related to the pandemic may disrupt healthcare delivery in the United States as well as the operations of regulatory bodies with responsibility for oversight of healthcare and health and medical products.
Such disruptions could result in the focus and prioritization of regulatory resources on emergent matters, which could divert regulatory resources away from more routine regulatory matters that are not COVID-19 related but that have the potential to impact our business.
For example, there have been and could continue to be delays in FDA review of applications for marketing authorization, including those which may be necessary for or in connection with proposed changes to our products or the changes to the processes by which they are manufactured.
It is unknown how long these disruptions could continue, were they to occur.
Any delay in regulatory review resulting from such disruptions could materially affect our ongoing device design, development, and commercialization plans.
Furthermore, the ongoing COVID-19 pandemic and associated shelter-in-place orders have and may continue to limit or restrict our ability to initiate, conduct or continue our clinical trials.
Delays and disruptions in our clinical trials have and may continue to result in delays for new or expanded marketing authorizations for our products, which could materially affect our development and commercialization plans for our products.
For example, we have experienced some delays in certain pivotal clinical trials for our next-generation CGM product.
Any prolonged economic downturn or recession could result in layoffs of employees and a significant increase in unemployment in the United States and elsewhere, which may continue even after the ongoing COVID-19 pandemic is contained.
An impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our customer.
As most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products, our customers may lose coverage to our products, which may harm our business and results of operations.
We currently utilize third parties to, among other things, manufacture components and materials for our devices, and to provide services such as sterilization services and we purchase these materials and services from numerous suppliers worldwide.
The global COVID-19 pandemic has and may continue to have an adverse impact on our manufacturing and distribution capabilities.
Disruptions relating to the ongoing COVID-19 pandemic could prevent employees, suppliers, distributors, and others from accessing manufacturing facilities and from transporting our products or the components required to manufacture our products.
For example, we have experienced some supply chain disruption due to the global restrictions resulting from the ongoing COVID-19 pandemic in the manufacture of our next-generation CGM product.
An excerpt. Shown here: 40 of 163 rewritten, 40 of 81 added and 40 of 129 removed. The counts are complete. For every sentence, read Item 1A. RISK FACTORS in the FY2023 filing and the FY2022 filing.
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
70 rewritten, 11 added, 53 removed, 124 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
| | | | We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation [removed: system,] [added: systems,] the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in 2018 and more recently received marketing clearance from the FDA on the Dexcom [removed: G7*®*] [added: G7®, or G7,] in December 2022. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries. | | |
While our significant accounting policies are described in Note 1 “Organization and Significant Accounting Policies” to the consolidated financial statements in Part II, Item 8 of this Annual [removed: Report,] [added: Report on Form 10-K,] we believe that the following accounting estimates are most critical to a full understanding and evaluation of our reported financial results.
Members of our senior management have discussed the development and selection of these critical accounting estimates and their disclosure in this Annual Report [added: on Form 10-K] with the Audit Committee of our Board of Directors.
An increase or decrease of 1% in our estimate of products sold subject to rebate during [removed: 2022,] [added: 2023,] holding all other assumptions constant, would increase or decrease revenue by approximately [removed: $19.1] [added: $22.9] million.
For more information, see *Revenue Recognition* in Note 1 “Organization and Significant Accounting Policies” to the consolidated financial statements in Part II, Item 8 of this Annual [removed: Report.][added: Report on Form 10-K.]
| Key Highlights for fiscal [removed: 2022] [added: 2023] include the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
We ended fiscal [removed: 2022] [added: 2023] with cash, cash equivalents and short-term marketable securities totaling [removed: $2.46] [added: $2.72] billion.
For discussion related to the results of operations and changes in financial condition for fiscal [removed: 2021] [added: 2022] compared to fiscal [removed: 2020] [added: 2021] refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our [removed: 2021] [added: 2022] Annual Report on Form 10-K, which was filed with the [removed: United States Securities and Exchange Commission] [added: SEC] on February [removed: 14, 2022.][added: 9, 2023.]
| Twelve Months Ended December 31, [removed: 2022] [added: 2023] Compared to Twelve Months Ended December 31, [removed: 2021] [added: 2022] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Twelve Months Ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | [removed: 2022] [added: 2023] - [removed: 2021] [added: 2022] | | | | | | | | |
| *(In millions, except per share amounts)* | | | [added: 2023] | | | | | | [added: % of Revenue (1)] | | | | | | [removed: (As Adjusted)*] [added: 2022] | | | | | | [added: % of Revenue (1)] | | | | | | [added: $ Change] | | | | | | [added: % Change] | | |
| Revenue | | | $ | [removed: 2,909.8] [added: 3,622.3] | | | | | 100 | | % | | | | $ | [removed: 2,448.5] [added: 2,909.8] | | | | | 100 | | % | | | | $ | [removed: 461.3] [added: 712.5] | | | | | [removed: 19] [added: 24] | | % |
| Cost of sales | | | [removed: 1,026.7] [added: 1,333.4] | | | | | | [removed: 35] [added: 37] | | % | | | | [removed: 768.0] [added: 1,026.7] | | | | | | [removed: 31] [added: 35] | | % | | | | [removed: 258.7] [added: 306.7] | | | | | | [removed: 34] [added: 30] | | % |
| Gross profit | | | [removed: 1,883.1] [added: 2,288.9] | | | | | | [removed: 64.7] [added: 63.2] | | % | | | | [removed: 1,680.5] [added: 1,883.1] | | | | | | [removed: 68.6] [added: 64.7] | | % | | | | [removed: 202.6] [added: 405.8] | | | | | | [removed: 12] [added: 22] | | % |
| Research and development | | | [removed: 484.2] [added: 505.8] | | | | | | [removed: 17] [added: 14] | | % | | | | [removed: 517.1] [added: 484.2] | | | | | | [removed: 21] [added: 17] | | % | | | | [removed: (32.9)] [added: 21.6] | | | | | | [removed: (6)] [added: 4] | | % |
| Selling, general and administrative | | | [removed: 1,000.2] [added: 1,185.4] | | | | | | [removed: 34] [added: 33] | | % | | | | [removed: 806.8] [added: 1,007.7] | | | | | | [removed: 33] [added: 35] | | % | | | | [removed: 193.4] [added: 177.7] | | | | | | [removed: 24] [added: 18] | | % |
| Total operating expenses | | | [removed: 1,491.9] [added: 1,691.2] | | | | | | [removed: 51] [added: 47] | | % | | | | [removed: 1,414.7] [added: 1,491.9] | | | | | | [removed: 58] [added: 51] | | % | | | | [removed: 77.2] [added: 199.3] | | | | | | [removed: 5] [added: 13] | | % |
| Operating income | | | [removed: 391.2] [added: 597.7] | | | | | | [removed: 13] [added: 17] | | % | | | | [removed: 265.8] [added: 391.2] | | | | | | [removed: 11] [added: 13] | | % | | | | [removed: 125.4] [added: 206.5] | | | | | | [removed: 47] [added: 53] | | % |
[removed: | Interest and other] [added: Other] income (expense), [removed: net | | | 18.0 | | | | | | 1 | | % | | | | (1.7) | | | | | | — | | % | | | | 19.7 | | | | | | | | |][added: net]
| Income before income taxes | | | [removed: 390.8] [added: 710.4] | | | | | | [removed: 13] [added: 20] | | % | | | | [removed: 256.8] [added: 390.8] | | | | | | [removed: 10] [added: 13] | | % | | | | [removed: 134.0] [added: 319.6] | | | | | | [removed: 52] [added: 82] | | % |
| Income tax expense [added: (benefit)] | | | [removed: 49.6] [added: 168.9] | | | | | | [removed: 2] [added: 5] | | % | | | | [removed: 39.9] [added: 49.6] | | | | | | 2 | | % | | | | [removed: 9.7] [added: 119.3] | | | | | | [removed: 24] | | [removed: %] |
| Net income | | | $ | [removed: 341.2] [added: 541.5] | | | | | [removed: 12] [added: 15] | | % | | | | $ | [removed: 216.9] [added: 341.2] | | | | | [removed: 9] [added: 12] | | % | | | | $ | [removed: 124.3] [added: 200.3] | | | | | [removed: 57] [added: 59] | | % |
| Basic net income per share | | | $ | [removed: 0.88] [added: 1.40] | | | | | | | | | | | $ | [removed: 0.56] [added: 0.88] | | | | | | | | | | | $ | [removed: 0.32] [added: 0.52] | | | | | [removed: 57] [added: 59] | | % |
| Diluted net income per share | | | $ | [removed: 0.82] [added: 1.30] | | | | | | | | | | | $ | [removed: 0.53] [added: 0.82] | | | | | | | | | | | $ | [removed: 0.29] [added: 0.48] | | | | | [removed: 55] [added: 59] | | % |
We expect that [added: the] revenue we generate from the sales of our products will fluctuate from quarter to quarter.
Our research and development expenses primarily consist of engineering and research expenses related to our [removed: continuous glucose monitoring] [added: sensing] technology, clinical trials, regulatory expenses, quality assurance programs, [removed: materials] [added: employee compensation,] and [removed: products for clinical trials.][added: business process outsourcers.]
Our selling, general and administrative expenses primarily consist of [removed: salary, fringe benefits and share-based] [added: employee] compensation for our executive, financial, sales, marketing, information technology and administrative functions.
[removed: Interest and other] [added: | Other] income (expense), [removed: net][added: net | | | 112.7 | | | | | | 3 | | % | | | | (0.4) | | | | | | — | | % | | | | 113.1 | | | | | | | | |]
[removed: Interest and other] [added: Other] income (expense), net consists primarily of interest [added: and dividend] income on our cash, cash equivalents and short-term marketable securities [removed: portfolio and] [added: portfolio,] foreign currency transaction gains and losses due to the effects of foreign currency [removed: fluctuations.][added: fluctuations, and interest expense related to our senior convertible notes.]
| | | | | | | Twelve Months Ended December 31, [removed: 2022] [added: 2023] Compared to Twelve Months Ended December 31, [removed: 2021] [added: 2022] | | |
| Revenue | | | | | | The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base, partially offset by mix shift and price associated with the evolution of our channel and product strategy. Disposable sensor and other revenue comprised approximately [removed: 87%] [added: 90%] of total revenue and Reusable Hardware revenue comprised approximately [removed: 13%] [added: 10%] of total revenue for the twelve months ended December 31, [removed: 2022.] [added: 2023.] Disposable sensor and other revenue comprised approximately [removed: 84%] [added: 87%] of total revenue and Reusable Hardware revenue comprised approximately [removed: 16%] [added: 13%] of total revenue for the twelve months ended December 31, [removed: 2021.] [added: 2022.] | | |
| Cost of [removed: Sales] [added: sales] & Gross [removed: Profit] [added: profit] | | | | | | Cost of sales and gross profit increased primarily due to an increase in sales volume. The decrease in gross profit margin in [removed: 2022] [added: 2023] compared to [removed: 2021] [added: 2022] was primarily driven by [added: the increase of the amortization of an intangible asset and] price, product, and channel mix [removed: changes and impact of foreign currencies on revenue.] [added: changes.] | | |
| Research and [removed: Development Expense] [added: development expense] | | | | | | Research and development expense [removed: decreased] [added: increased] primarily due to [removed: $43.0] [added: $33.7] million in [added: compensation-related costs most notably due to higher headcount, partially offset by $15.9 million of] lower third party and consulting fees [removed: most notably] [added: primarily] related to software development for new products and significant [removed: enhancements, $19.9 million in lower costs related to set-up and validation costs for new CGM equipment, and $9.7 million in lower clinical trials costs, partially offset by $26.5 million in compensation-related costs due to higher headcount.] [added: enhancements.] We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy. | | |
| [removed: Interest and Other Income (Expense), Net] [added: Other income (expense), net] | | | | | | [removed: Interest and other] [added: Other] income (expense), net, increased primarily due to [removed: $22.1] [added: $111.2] million in interest [added: and dividend] income on our [removed: short-term] [added: cash, cash equivalents, and] marketable securities [removed: portfolio, partially offset by foreign currency transaction gains and losses due to the effects of foreign currency fluctuations.] [added: portfolio.] The increase in interest income was [removed: primarily] related to a [removed: significant increase] [added: change] in market interest rates, as well as an increase in the average invested balances during [removed: 2022] [added: 2023] compared to [removed: 2021.] [added: 2022.] | | |
| Income [removed: Tax Expense] [added: tax expense (benefit)] | | | | | | We recorded income tax expense on pre-tax book income for the twelve months ended December 31, [removed: 2022] [added: 2023] and December 31, [removed: 2021.] [added: 2022.] The income tax expense we recorded for [removed: 2022] [added: 2023] is primarily attributable to income tax expense from normal, recurring operations [added: as well as income taxes related to an intra-entity transfer of certain intellectual property partially] offset by excess tax benefits recognized for share-based compensation for employees (net of disallowed executive compensation) and the Verily milestone payment, and generation of research and development tax credits. The income tax expense we recorded for [removed: 2021] [added: 2022] is primarily attributable to income tax expense from normal, recurring operations [added: partially] offset by excess tax benefits recognized for employee share-based [removed: compensation, generation] [added: compensation (net] of [removed: research and development tax credits,] [added: disallowed executive compensation)] and [removed: a one-time tax benefit related to tax law changes.] [added: the Verily milestone.] | | |
We will be exposed to additional foreign currency exchange risk related to our [removed: foreign] [added: international] operations [removed: when] [added: as] we [removed: begin] [added: expand our] manufacturing [removed: in Malaysia] [added: internationally] and as our business continues to increase in [added: international markets.]
See “Foreign Currency Exchange Risk” in Part II, Item 7A of this Annual Report [added: on Form 10-K] for more information.
Our cash, cash equivalents and short-term marketable securities totaled [removed: $2.46] [added: $2.72] billion as of December 31, [removed: 2022.][added: 2023.]
None of those funds were restricted and [removed: $2.29] [added: $2.54] billion (approximately 93%) of those funds were located in the United States.
For the twelve months ended December 31, [removed: 2022,] [added: 2023,] we had positive cash flows of [removed: $669.5] [added: $748.5] million from operating activities.
| $3.62 billion | | | | | | | | | $2.29 billion | | | | | | | | | $597.7 million | | | | | | | | | $541.5 million | | | | | | | | | $748.5 million | | |
| up 24% from 2022 | | | | | | | | | up 22% from 2022 | | | | | | | | | up 53% from 2022 | | | | | | | | | up 59% from 2022 | | | | | | | | | up 12% from 2022 | | |

| Selling, general and administrative expense | | | | | | Selling, general and administrative expense increased primarily due to $88.8 million in compensation-related costs most notably due to higher headcount, $37.8 million in legal expense primarily related to a patent infringement lawsuit, and $36.6 million in advertising and marketing costs associated with global product launches. | | |
We used $289.9 million of the net proceeds from the offering of the 2028 Notes to purchase capped call transactions and repurchase shares of our common stock in May 2023.
In connection with the 2028 Notes offering we purchased the 2028 Capped Calls.

| \- | | | $236.6 million in capital expenditures | | | \- | | | $138.5 million in net purchases of marketable securities | | | | | | | | | | | |
| + | | | $26.6 million in proceeds from issuance of common stock under our employee stock plans | | | \- | | | $557.7 million in purchases of treasury stock | | | | | | | | | | | |
| \- | | | $688.7 million in purchases of treasury stock | | | | | | | | | | | | | | | | | |
| \- | | | $101.3 million in purchases of capped call transactions | | | | | | | | | | | | | | | | | |
The risks and uncertainties include, among other things, impacts on our business due to health pandemics or other contagious outbreaks, such as the ongoing COVID-19 pandemic.
| | | | Impact of Current Events | | | | | | | | |
| | | | During 2020, 2021, and 2022, we have been subject to challenging social and economic conditions created as a result of the novel strain of coronavirus, SARS-CoV-2 and its variants, or COVID-19. These conditions continue to create various financial impacts to our operations by necessitating precautions for our personnel to operate safely both in person as well as remotely. Costs incurred include items like incremental payroll costs, consulting support, IT infrastructure and facilities-related costs. | | | | | | | | |
| | | | As the result of the COVID-19 pandemic, and in coordination with an FDA communication of enforcement discretion, we made Dexcom CGM systems available for use in hospital settings and other healthcare facilities. The extent of the impact of the ongoing COVID-19 pandemic on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers and our sales cycles, employee or industry events, and effect on our vendors, all of which are uncertain and cannot be predicted. The ongoing COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we have experienced moderate disruptions in our global operations. We have experienced and may experience constrained supply or curtailed customer demand, including due to customer loss of private health insurance coverage for our products, that could materially adversely impact our business, results of operations and overall financial performance in future periods. We currently utilize third parties to, among other things, manufacture components and materials for our devices, and to provide services such as sterilization services and we purchase these materials and services from numerous suppliers worldwide. | | | | | | | | |
| | | | The ongoing COVID-19 pandemic has and may continue to have an adverse impact on our manufacturing and distribution capabilities. Disruptions relating to the ongoing COVID-19 pandemic, including shelter-in-place orders in the U.S. and other countries, could prevent employees, suppliers, distributors, and others from accessing manufacturing facilities and from transporting our products or the components required to manufacture our products. For example, we have experienced some supply chain disruption due to the global restrictions resulting from the ongoing COVID-19 pandemic in the manufacturing of our next-generation CGM product. Further, worldwide supply chain disruption relating to the ongoing COVID-19 pandemic has resulted in product shortages that has and may continue to impact our ability to manufacture our devices. As of the filing date of this Annual Report, the extent to which the ongoing COVID-19 pandemic may impact our financial condition or results of operations or guidance is uncertain. The effect of the ongoing COVID-19 pandemic will not be fully reflected in our results of operations and overall financial performance until future periods. See “Risk Factors” in Part I, Item 1A of this Annual Report for further discussion of the possible impact of the ongoing COVID-19 pandemic on our business. | | | | | | | | |
| | | | In addition, the global supply chain shortages and disruptions are impacting our ability to obtain certain raw materials and components used in our products. We depend on single- or sole-source suppliers to obtain sufficient quantities of these components that are critical to manufacturing our products. Disruptions at these suppliers could lead to a similar disruption in our ability to manufacture products on time to meet consumer demand. In addition, these supply chain constraints may result in higher costs due to a more competitive supply environment. These conditions may impact our gross margin. | | | | | | | | |
| $2.91 billion | | | | | | | | | $1.88 billion | | | | | | | | | $391.2 million | | | | | | | | | $341.2 million | | | | | | | | | $669.5 million | | |
| up 19% from 2021 | | | | | | | | | up 12% from 2021 | | | | | | | | | up 47% from 2021 | | | | | | | | | up 57% from 2021 | | | | | | | | | up 51% from 2021 | | |
| Business Trends | | | | | | | | | | | | | | |
In addition to the general impacts of current events on our company as described in the Overview, looking ahead we expect our business could be affected by the following:
- Increase in the worldwide incidence of people diagnosed with diabetes and costs related to the management and treatment of diabetes.
- Changes in medical reimbursement policies and programs.
- Growing demand for digital health technologies by both healthcare providers and consumers to reduce costs.
- An expected interest in empowering consumers to make better-informed decisions about their own health and new potential options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional health care settings.
- Growing research and interest in the use of CGM technology outside of the ambulatory care setting, including use by hospital systems.
- Continued product innovation and competition from other CGM device makers.
- Our ability to scale efficiently with the construction of our production facility in Malaysia.
| | | | 2022 | | | | | | % of Revenue (1) | | | | | | 2021 | | | | | | % of Revenue (1) | | | | | | $ Change | | | | | | % Change | | |
| Collaborative research and development fee | | | — | | | | | | — | | % | | | | 87.1 | | | | | | 4 | | % | | | | (87.1) | | | | | | | | |
| Amortization of intangible assets | | | 7.5 | | | | | | — | | % | | | | 3.7 | | | | | | — | | % | | | | 3.8 | | | | | | | | |
| Interest expense | | | (18.6) | | | | | | (1) | | % | | | | (18.8) | | | | | | (1) | | % | | | | 0.2 | | | | | | (1) | | % |
| Loss on extinguishment of debt | | | — | | | | | | — | | % | | | | (0.1) | | | | | | — | | % | | | | 0.1 | | | | | | | | |
| Income from equity investments | | | 0.2 | | | | | | — | | % | | | | 11.6 | | | | | | — | | % | | | | (11.4) | | | | | | (98) | | % |
| * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements in Part II, Item 8 of this Annual Report for further information. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development expenses are primarily related to employee compensation, including salary, fringe benefits, share-based compensation, and temporary employee expenses.
We also incur significant expenses to operate our clinical trials including budgeted clinical site compensation and reimbursement, study monitoring and oversight expenses, clinical trial product and associated travel expenses.
Our research and development expenses also include fees for design services, contractors and development materials.
Interest expense
Interest expense is comprised primarily of costs related to our senior convertible notes.
| Collaborative Research and Development Fee | | | | | | Collaborative research and development fees of $87.1 million for the twelve months ended December 31, 2021 represents expense incurred in the fourth quarter of 2021 associated with a contingent milestone for regulatory approval under the Restated Collaboration Agreement. See Note 2 “Collaboration with Verily Life Sciences” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information. | | |
| Selling, General and Administrative Expense | | | | | | Selling, general and administrative expense increased primarily due to $54.1 million in compensation-related costs most notably due to higher headcount, $26.0 million in advertising and marketing costs due to an increase in worldwide marketing campaigns, $23.0 million in long-lived asset impairment charges, $21.5 million in legal expense related to litigation, $13.0 million in travel and entertainment expenses, and $5.8 million in depreciation expense due to higher property and equipment balances and accelerated depreciation related to business transition activities. | | |
| Income from Equity Investments | | | | | | Income from equity investments of $11.6 million for the twelve months ended December 31, 2021 consisted solely of realized gains from the sale of an equity investment. | | |
markets outside of the United States.
We used $282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due 2022, or 2022 Notes.
The 2023 Note Hedge is expected to reduce the potential equity dilution upon any conversion of the 2023 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2023 Notes.
On July 26, 2022, a duly authorized committee of our Board of Directors authorized a share repurchase program of up to $700.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2023.
As of December 31, 2022, approximately $142.3 million remained available for repurchase pursuant to our share repurchase program.
We may elect to settle the remaining principal amount outstanding of the 2023 Notes with cash and/ or shares of Dexcom common stock prior to maturity once certain conditions are met.
As of December 31, 2022, we have outstanding senior convertible notes that will mature in November 2025 for the 2025 Notes.
As of January 1, 2022, for U.S. tax purposes, research and development expenses are required to be capitalized and amortized rather than immediately deducted.
An excerpt. Shown here: 40 of 70 rewritten, all 11 added and 40 of 53 removed. The counts are complete. For every sentence, read Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS in the FY2023 filing and the FY2022 filing.
Page headers and footers: 2 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.


Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
4 rewritten, 2 added, 5 removed, 20 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
[removed: transactions] [added: The 2023 Warrants] could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given quarterly or annual measurement period exceeds the strike price of the warrants.
We [removed: will be] [added: are] exposed to additional foreign currency exchange risk related to our foreign operations [removed: when] [added: as] we [removed: begin] [added: are now] manufacturing [removed: in Malaysia] [added: internationally] and as our business continues to increase in markets outside of the United States.
We also record exchange rate fluctuations resulting from the translation of the short-term intercompany balances between domestic entities and our international subsidiaries as foreign currency transaction gains or losses and include them in [removed: interest and] other income (expense), net in our consolidated statements of operations.
The derivative gains and losses are included in [removed: interest and] other income (expense), net in our consolidated statements of operations.
We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management.
The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, with such reduction and/or offset subject to a cap.
In order to reduce potential equity dilution, in connection with the issuance of the 2023 Notes we entered into the 2023 Note Hedge which entitles us to purchase shares of our common stock.
Upon conversion of the 2023 Notes, the 2023 Note Hedge is expected to reduce the equity dilution if the daily volume-weighted average price per share of our common stock exceeds the strike price of the hedge.
We also entered into warrant transactions with the counterparties of the 2023 Note Hedge entitling them to acquire shares of our common stock.
The warrant
Changes in foreign currencies impact currency translation and had a slightly negative effect on our revenues and gross profit margins.
Item 1. BUSINESS
90 rewritten, 45 added, 89 removed, 473 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for [removed: use by people with] [added: the management of] diabetes [removed: and] by [removed: healthcare providers.][added: patients, caregivers, and clinicians around the world.]
We received approval from the [removed: United States] Food and Drug Administration, or FDA, and commercialized our first product in 2006.
We [removed: received FDA marketing authorization and] launched our latest generation [removed: system,] [added: systems,] the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in 2018 and more recently received marketing clearance from the FDA on the Dexcom [removed: G7*®*] [added: G7*®*, or G7,] in December 2022.
As we [added: continue to] establish an installed base of customers using our products, we expect to generate an increasing portion of our revenues through recurring sales of our disposable sensors.
Dexcom G7 is [removed: now] cleared in the United States for all people with diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution.
With an overall Mean Absolute Relative Difference, or MARD, of 8.2%, [added: as well as 94.1% of values within 20% of their comparator,] Dexcom G7 is the most accurate CGM cleared by the [removed: FDA,] [added: FDA] and is clinically proven to lower A1C (a blood test that provides information about average levels of blood glucose, over the prior three months), reduce hyper- and [removed: hypoglycemia] [added: hypoglycemia,] and increase time in range.
The G7 also has a number of new or improved features compared to our prior generation [removed: devices.][added: devices:]
- New indications for use. Indicated in the United States for wear on the back of the upper arm for ages 2 years and older or the upper buttocks for ages [removed: 2-17] [added: 2-6] years old.
[removed: The general purpose of these development and commercial relationships is] to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner’s insulin delivery device to receive and display glucose readings from our transmitter and, in [added: some cases, use the glucose readings for semi-automated insulin delivery.]
[removed: In addition to these major partners,] [added: We have existing insulin delivery partnerships, and] we are [added: also] working with other companies that are pursuing varying strategies surrounding semi-automated insulin delivery and data analytics to improve outcomes and ease-of-use in diabetes management.
In consideration of Verily’s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we have made upfront, incentive, [removed: and] product regulatory approval milestone payments, and [removed: will make potential additional milestone payments for future] [added: a] sales-based [removed: milestones.][added: milestone payment.]
If we elect to make [removed: these] [added: a] milestone [removed: payments] [added: payment] in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, adjusted for stock splits, dividends, and the like.
We intend to pay the [added: remaining] sales-based contingent [removed: milestones] [added: milestone] in shares of our common stock.
See Note 2 “Development and Other Agreements” to the consolidated financial statements in Part II, Item 8 of this Annual Report and Exhibit [removed: 10.15] [added: 10.14] of this Annual Report [added: on Form 10-K] for a further description of the Restated Collaboration Agreement, including the number of shares of stock for milestone payments.
According to the Centers for Disease Control and Prevention, or CDC, in its National Diabetes Statistics Report, [removed: 2022,] [added: 2023,] or the [removed: 2022] [added: 2023] CDC Report, crude estimates for the prevalence of diabetes in the United States as of [removed: 2019] [added: 2021] include [removed: 37.3] [added: 38.4] million people with diabetes, of which [removed: 28.7] [added: 29.7] million people have diagnosed diabetes.
[removed: According to the ADA, one in every four healthcare dollars] was spent on treating people with diabetes in [removed: 2017,] [added: 2022,] and the direct medical costs and indirect expenditures attributable to diabetes in the United States were an estimated [removed: $327] [added: $413] billion, an inflation-adjusted increase of approximately [removed: 26%] [added: 35%] since 2012.
Of the [removed: $327] [added: $413] billion in overall expenses, the ADA estimated that approximately [removed: $237] [added: $307] billion were direct costs associated with diabetes care, chronic complications and excess general medical costs, and [removed: $90] [added: $106] billion were indirect costs.
The ADA also found that in [removed: 2017,] [added: 2022,] average medical expenditures among people with diagnosed diabetes were [removed: 2.3] [added: 2.6] times higher than for people without diabetes.
According to the [removed: 2022] [added: 2023] CDC Report, as of [removed: 2019] [added: 2021] there were an estimated [removed: 1.8] [added: 2.0] million adults and youth with diagnosed Type 1 diabetes in the United States.
Alerts triggered by existing or impending abnormal glucose values are associated with less exposure to hypo- and hyperglycemia in large real-world data sets, and multi-device integration [removed: allows some CGM systems to communicate with automated insulin delivery systems.]
Our current target market consists primarily of people with Type 1 and Type 2 diabetes who utilize insulin [removed: therapy.][added: therapy as well as certain non-insulin using people with diabetes that struggle with hypoglycemia.]
We also believe that our CGM systems are beginning to have a positive impact on the broader Type 2 population that does not utilize [removed: insulin,] [added: insulin or have hypoglycemia risk,] a group that we estimate to be [removed: approximately 30] [added: greater than 25] million people in the United States alone.
In the future, we plan to expand our product offering [added: to people who are pregnant] and cleared/approved indications to address people with pre-diabetes, people who are obese, [removed: people who are pregnant,] and people in the hospital setting.
Our current CGM systems wirelessly transmit information from the [removed: transmitter, which sits in a pod atop the sensor,] [added: transmitter] to our receiver or to a compatible mobile device.
We plan to develop future generations of technologies [added: that are] focused on improved performance and convenience [added: and] that will enable intelligent insulin administration.
We intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights [removed: with the potential to] [added: that can] inform patient behavior.
We are also exploring how to extend our offerings to other [removed: populations,] [added: opportunities,] including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting.
We believe that focusing efforts on these participants is important given the instrumental role they each play in the decision-making process for diabetes therapy, and to ensure that health care [added: professionals and patients are knowledgeable about our products and their functionality.]
In jurisdictions where DTC marketing is permitted, we currently focus on reaching people with Type 1 and [removed: insulin intensive] [added: people with] Type 2 [removed: diabetes.][added: diabetes who use insulin.]
Medtronic markets and sells a standalone glucose monitoring product called Guardian Connect, both internationally and in the United [removed: States.][added: States, and a disposable CGM system called Simplera in international markets.]
We currently manufacture our products at our headquarters in San Diego, California and at our manufacturing [removed: facility] [added: facilities] in Mesa, [removed: Arizona,] [added: Arizona and Penang, Malaysia,] where we [added: collectively] have approximately [removed: 46,800] [added: 65,900] square feet of laboratory space and approximately [removed: 85,200] [added: 155,700] square feet of controlled environment rooms.
There are technical challenges to increasing manufacturing capacity, finding or enhancing new manufacturing facilities capable of meeting regulatory requirements, [removed: U.S. state] [added: government] licensure of manufacturing facilities, equipment design and automation, material procurement, problems with production yields, and quality control and assurance.
As of December 31, [removed: 2022,] [added: 2023,] those single sources include suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors.
For additional information, please see our Risk Factor entitled, “*We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business*.” [removed: For supply risks related to COVID-19, see our Risk Factor entitled “*The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales*.”]
We also have coverage under certain international markets and Medicaid coverage in [removed: about] [added: approximately] 45 states.
As of December 31, [removed: 2022,] [added: 2023,] the eight largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of continuous glucose monitoring devices.
We have personnel with reimbursement expertise to assist customers in obtaining reimbursement from [added: private third-party payors.]
Our issued patents as of December 31, [removed: 2022] [added: 2023] are set to expire over a range of years, from [removed: 2023] [added: 2024] with respect to some of our earlier patents, to [removed: 2041,] [added: 2042,] subject to any extensions.
The steps we have taken may not prevent the misappropriation of our intellectual property, particularly in [removed: foreign] [added: international] countries where the laws may not protect our proprietary rights as fully as in the United States.
We cannot guarantee that employees and third parties will abide by the confidentiality [removed: or assignment terms of these agreements.]
In the United States, the G7 is covered by Medicare and Medicaid in the majority of states and by commercial insurers, subject to satisfaction of certain eligibility and coverage criteria for individuals with both Type 1 and Type 2 diabetes.
*Dexcom Stelo*®
We are pursuing regulatory approvals for Dexcom Stelo, our first product designed specifically for people with type 2 diabetes who do not use insulin and are not at risk for hypoglycemia.
Stelo was submitted for FDA review in the fourth quarter of 2023.
In November 2023, we obtained CE Mark approval for Dexcom ONE+.
This updated version of our Dexcom ONE system builds upon the software experience of Dexcom ONE with certain additional features, while allowing customers to adopt the all-in-one wearable technology of our G7 CGM system.
The general purpose of these development and commercial relationships is
In the future, we may make a potential additional milestone payment for a future sales-based milestone.
According to the American Diabetes Association, or ADA, one in every four healthcare dollars

allows some CGM systems to communicate with automated insulin delivery systems.
- Supporting innovation through technology integration partnerships.
Likewise, Abbott Diabetes Care has
received FDA clearance to integrate certain versions of their Libre sensors into automated insulin delivery systems and is pursuing such integrations with third-party insulin delivery devices.
In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing.
We are also expanding our facility in Mesa, Arizona to scale up manufacturing capacity and plan to begin construction of a new facility in Ireland.
We anticipate that the new facilities and the Mesa capacity scale-up will add substantial manufacturing capacity.
Medicare covers the CGM system, which includes supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category.
Previously, Medicare coverage for CGM was only available to Medicare patients who take at least three doses of insulin a day, limiting CGM reimbursement for Medicare beneficiaries with intensive Type 1 and 2 diabetes.
The Local Coverage Determination, or LCD, that the Centers for Medicare & Medicaid Services released in April 2023 extends Medicare CGM coverage to all patients using insulin.
Further, the LCD also allows coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia.
For additional information on third-party reimbursement, please see our see Risk Factors in the section entitled “*Risks Related to Pricing and Reimbursement*.”
or assignment terms of these agreements.
payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid.
Inducement CMP.
*HIPAA and Other U.S. Privacy Laws and Regulations.* Numerous federal and state laws, rules and regulations govern the collection, dissemination, use, privacy, security and confidentiality of personal information.
HIPAA, in addition to the criminal powers above, extensively regulates the use and disclosure of individually identifiable health information, through the Privacy, Security, and Breach Notification Rules.
We are a covered entity under HIPAA because we are a health care provider that engages in certain electronic standard transactions.
We have assessed our responsibilities under the bulletin and undertaken a number of initiatives to support our compliance with HIPAA and other requirements relating to online tracking technologies, including updates to our cookie banners and preference center.
These steps are in addition to measures we had taken previously and we continue to evaluate our compliance with applicable laws and adjust our practices to address developments in the field over time.
disclosure of personally identifiable information.
Specifically, FTC has asserted authority and issued enforcement actions in response to actual or perceived unfair or deceptive practices by a company in the handling of consumer information.
The FTC has also pursued enforcement actions against companies for violations of its Health Breach Notification Rule and the Children’s Online Privacy Protection Act.
Our use of personal information is also subject to our published privacy policies and notices.
Several other states have enacted, or are proposing to enact, their own comprehensive privacy laws.
A particular focus of legislatures appears to be consumer health data which is not subject to HIPAA, as evidenced by passage of the Washington My Health My Data Act and Nevada Senate Bill 370.
The effects of state data protection laws are significant and have required us to modify our data processing practices.
Certain states also
The MDR initially provided three years for transition and compliance, which was subsequently extended to May 2026, December 2027, or December 2028, depending on the device classification.
data outside of Europe.
The mailing address of our headquarters is 6340 Sequence Drive, San Diego, California, 92121 and our telephone number at that location is (858) 200-0200.
Our Internet website address is www.dexcom.com.
We provide free access to various reports that we file with or furnish to the SEC through our website, as soon as reasonably practicable after they have been filed or furnished.
These reports include, but are not limited to, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports.
Information on our website does not constitute part of this Annual Report on Form 10-K or other report we file or furnish with the SEC.
The reports are also available at www.sec.gov.
Also available on our website are printable versions of our Audit Committee charter, Compensation Committee charter, Nominating and Corporate Governance Committee charter, Technology Committee charter, Corporate Governance Guidelines and Code of Conduct and Business Ethics.
Stockholders may request copies of these documents by mail or telephone, at the address or phone number provided above.
We are working to obtain reimbursement coverage by Medicare and Medicaid and by commercial insurers in the United States.
some cases, use the glucose readings for semi-automated insulin delivery.
Currently, we have announced significant insulin delivery partnerships with Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes and The Ypsomed Group.
The 2022 CDC Report also lists diabetes as the seventh leading cause of death by disease in the United States, excluding comorbidities associated with the disease.
The report states that diabetes is the primary cause of death for more than 87,000 Americans each year, and contributes to the death of more than 280,000 Americans annually.
According to the Congressional Diabetes Caucus website, diabetes is the leading cause of kidney failure, adult-onset blindness, lower-limb amputations, and a significant cause of heart disease, stroke, high blood pressure and nerve damage.
According to the IDF, there were an estimated 6.7 million deaths attributable to diabetes globally in 2021 between the ages of 20 and 79 years.
According to JDRF, greater than 60,000 people are diagnosed with Type 1 diabetes each year in the United States.
In addition, according to the ADA in 2019, nearly 18,000 youth are newly diagnosed with Type 1 diabetes every year in the United States.
However, according to an article published in *The New England Journal of Medicine* in November 2014, in two national registries, only 13% to 15% of people with diabetes met treatment guidelines for good glycemic control, and more than 20% had very poor glycemic control.
- Supporting innovation through technology integration partnerships such as our current partnerships with Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes, The Ypsomed Group and others globally.
Disposable Sensor and Reusable Transmitter
Our sensor includes a tiny wire-like electrode coated with our sensing membrane system.
This disposable sensor comes packaged with an integrated insertion device and is contained in a small plastic housing platform, or pod.
The base of the pod has adhesive that attaches it to the skin.
The sensor is intended to be easily and reliably inserted by the user by exposing the adhesive, placing the pod against the surface of the skin of the abdomen or upper buttocks for people ages 2-17, and pushing down on the insertion device.
The insertion device first extends a narrow gauge needle containing the sensor into the subcutaneous tissue and then retracts the needle, leaving behind the sensor in the tissue and the pod adhered to the skin.
The user then disposes of the insertion device and snaps the transmitter to the pod.
After a stabilization period, the user will begin receiving CGM data on his or her mobile device or dedicated receiver through the ten-day usage period.
Our G6 and G7 systems have labeling from the FDA and CE Mark permitting their use as a replacement for finger sticks for making therapeutic adjustments.
The disposable sensors contained in the G6 and G7 systems respectively are each intended to function for up to ten days, after which the sensor should be replaced.
To replace a sensor, the user simply removes the pod and attached sensor from the skin and discards them while retaining the reusable transmitter.
A new sensor and pod can then be inserted and used with the same receiver and transmitter for a subsequent use period.
Handheld Receiver
Our small handheld receiver is carried by the user and wirelessly receives continuous glucose values from the transmitter.
Proprietary algorithms and software, developed from our extensive database of continuous glucose data from clinical trials, are programmed into the G6 and G7 transmitter to process the glucose data from the sensor, which then sends the processed glucose data to the receiver and displays it on a user-friendly graphical user interface.
With a push of a button, the user can access their current glucose value and one-, three-, six-, twelve- and twenty-four-hour trended data.
Additionally, when glucose values are inappropriately high or low, the receiver provides an audible alert or vibrates.
The receiver is a self-contained, durable unit with a rechargeable battery.
professionals and patients are knowledgeable about our products and their functionality.
We are also near completion of the initial phase of construction of a new facility in Malaysia that we anticipate will add substantial manufacturing capacity.
In January 2017, the Centers for Medicare and Medicaid, or CMS, established a classification of “Therapeutic Continuous Glucose Monitors” as durable medical equipment under Medicare Part B, subject to payment by Medicare under certain coverage conditions which are determined and updated by CMS, by local Medicare Administrative Contractors or on a patient claim by claim basis.
An excerpt. Shown here: 40 of 90 rewritten, 40 of 45 added and 40 of 89 removed. The counts are complete. For every sentence, read Item 1. BUSINESS in the FY2023 filing and the FY2022 filing.
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.

Item 3. LEGAL PROCEEDINGS
4 rewritten, 34 added, 0 removed, 2 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
[removed: During the year ended December 31, 2022,] [added: Since June 2021,] we and certain Abbott Diabetes Care, Inc. (“Abbott”) entities [added: have] served [removed: complaints for] patent [removed: infringement, validity and other patent related actions] [added: infringement complaints] against each other in multiple [removed: jurisdictions, inside and outside the United States.][added: jurisdictions against certain continuous glucose monitoring products of each company.]
We intend to [removed: vigorously pursue our claims and defenses in these cases to] protect our intellectual property and [removed: to] defend against Abbott’s [removed: infringement allegations.][added: claims vigorously in all of these actions.]
We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial [removed: condition] [added: condition,] or results of operations.
There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial [removed: condition] [added: condition,] or results of operations.
In June 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (National Court (“N.C.”) in Mannheim).
In May 2023, we filed additional patent infringement actions in Germany (N.C. in Munich).
In July and August 2023, we initiated patent infringement litigation in the United Patent Court (“UPC”) (Paris & Munich) and in Spain (Commercial Courts of Barcelona).
In October and November 2023, we initiated patent infringement litigation in Germany (N.C. in Munich) and in the UPC (Paris & Munich).
In January 2024, we initiated patent infringement litigation in Germany (N.C. in Hamburg).
In July 2021, one day after we initiated litigation in the U.S.D.C., Western District of Texas, Abbott initiated patent infringement litigation against Dexcom in the United States (U.S.D.C., Delaware (“D1”)).
Shortly thereafter, Abbott filed additional patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales) and Germany (N.C. in Mannheim and Dusseldorf).
In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in the Business and Property Courts of England and Wales.
Three trials on liability have already been conducted in the United Kingdom.
On October 18, 2023, judgment was handed down in favor of Dexcom in one of these trials.
On January 15, 2024, judgment was handed down invalidating both Abbott and Dexcom’s patents in another one of these trials.
The parties are awaiting rulings on the remaining trial.
Dexcom and Abbott sought injunctive relief and monetary damages as a result of their respective claims.
In December 2021, Abbott filed a breach of contract lawsuit against Dexcom in the United States (U.S.D.C., District of Delaware) alleging that Dexcom breached the parties' Settlement and License Agreement dated July 2, 2014 (“SLA”).
The U.S.D.C., District of Delaware consolidated Abbott’s breach of contract lawsuit with Dexcom’s patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas (“D3”).
Dexcom asserted counterclaims that Abbott also breached the SLA.
A jury trial on Abbott’s breach of contract claims commenced on July 10, 2023.
On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims.
In April 2022, Abbott initiated the inter partes review (“IPR”) process on the asserted claims of Dexcom’s patents in D3.
The U.S. Patent and Trademark Office (the “PTO”) denied institution of one of Dexcom’s patents and instituted IPR on the other four.
Ultimately, in November 2023, the PTO issued its Final Written Decision, upholding claims of two Dexcom patents to be patentable, which cover factory calibration and certain alarms and alerts, and two to be unpatentable, which cover certain sensor code and sensor configurations.
We will continue to enforce the remaining claims of the patents asserted in Delaware with trial set for February 2025.
In February 2023, Abbott filed patent infringement litigation against us in Germany (N.C. in Hamburg and Munich).
In March 2023, Abbott filed a patent infringement litigation in the United States (U.S.D.C., Delaware (“D4”)) and we filed counterclaims for patent infringement in that action in June 2023.
In June 2023, Abbott filed patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales).
In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction.
Abbott’s patent infringement action, “D1", against Dexcom is currently scheduled for trial in the U.S.D.C., District of Delaware on March 11, 2024.
In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott’s patents on factory calibration and Abbott dropped four other patents from the litigation.
The claims currently being litigated are isolated to the inserter mechanism and the wearable seal and mount of Dexcom’s G6.
Commencing in January 2024, Abbott has several patent infringement hearings against Dexcom in Germany (N.C. in Hamburg and Munich) wherein Abbott is seeking damages and injunctive relief.
On January 31, 2024, the Court in Munich in two such hearings provided Dexcom additional time to brief certain issues Abbott raised late in the proceedings, thus postponing a decision in both proceedings until May 2024.
In March and April of 2024, Dexcom has several patent infringement hearings in the N.C. in Mannheim and Munich against Abbott, wherein Dexcom is seeking damages and injunctive relief.
Dexcom has hearings in May and June 2024 in its first two proceedings in the UPC and in July 2024 in the N.C. in Munich.
Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time.
Cover and table of contents
44 rewritten, 29 added, 4 removed, 67 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
For the fiscal year ended December 31, [removed: 2022][added: 2023]
(Address of principal executive [removed: offices)][added: offices, including zip code)]
| Common Stock, $0.001 Par Value Per Share | | | DXCM | | | [removed: The] Nasdaq [removed: Stock] [added: Global Select] Market [removed: LLC] | | |
[removed: Large accelerated filer ☒ Accelerated filer ☐] [added: |] Non-accelerated filer [added: | | |] ☐ [added: | | | | | |] Smaller reporting company [removed: ☐ Emerging growth company] [added: | | |] ☐ [added: | | |]
As of June 30, [removed: 2022,] [added: 2023,] the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately [removed: $29.1] [added: $49.4] billion based on the closing sales price of [removed: $74.53] [added: $128.51] per share as reported on the Nasdaq Global Select [removed: Market.][added: Market on that date.]
| Class | | | | | | Outstanding at February [removed: 2, 2023] [added: 1, 2024] | | |
| Common stock, $0.001 par value per share | | | | | | [removed: 386,413,690] [added: 385,515,421] | | |
Portions of the registrant’s definitive proxy statement relating to its [removed: 2023] [added: 2024] Annual Meeting of Stockholders (the “Proxy Statement”) are incorporated by reference in Part III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item [removed: numbers.][added: numbers, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.]
| [ITEM [removed: 1.](#i6eef640963c94f0198129aab5beef55a_16)] [added: 1.](#i70f957301cc34339a22f629982cd0734_16)] | | | [removed: [Business](#i6eef640963c94f0198129aab5beef55a_16)] [added: [Business](#i70f957301cc34339a22f629982cd0734_16)] | | | [removed: [5](#i6eef640963c94f0198129aab5beef55a_16)] [added: [6](#i70f957301cc34339a22f629982cd0734_16)] | | |
| [ITEM [removed: 1A.](#i6eef640963c94f0198129aab5beef55a_22)] [added: 1A.](#i70f957301cc34339a22f629982cd0734_19)] | | | [Risk [removed: Factors](#i6eef640963c94f0198129aab5beef55a_22)] [added: Factors](#i70f957301cc34339a22f629982cd0734_19)] | | | [removed: [27](#i6eef640963c94f0198129aab5beef55a_22)] [added: [26](#i70f957301cc34339a22f629982cd0734_19)] | | |
| [ITEM [removed: 1B.](#i6eef640963c94f0198129aab5beef55a_25)] [added: 1B.](#i70f957301cc34339a22f629982cd0734_67)] | | | [Unresolved Staff [removed: Comments](#i6eef640963c94f0198129aab5beef55a_25)] [added: Comments](#i70f957301cc34339a22f629982cd0734_67)] | | | [removed: [70](#i6eef640963c94f0198129aab5beef55a_25)] [added: [67](#i70f957301cc34339a22f629982cd0734_67)] | | |
| [ITEM [removed: 2.](#i6eef640963c94f0198129aab5beef55a_28)] [added: 2.](#i70f957301cc34339a22f629982cd0734_70)] | | | [removed: [Properties](#i6eef640963c94f0198129aab5beef55a_28)] [added: [Properties](#i70f957301cc34339a22f629982cd0734_70)] | | | [removed: [70](#i6eef640963c94f0198129aab5beef55a_28)] [added: [69](#i70f957301cc34339a22f629982cd0734_70)] | | |
| [ITEM [removed: 3.](#i6eef640963c94f0198129aab5beef55a_31)] [added: 3.](#i70f957301cc34339a22f629982cd0734_73)] | | | [Legal [removed: Proceedings](#i6eef640963c94f0198129aab5beef55a_31)] [added: Proceedings](#i70f957301cc34339a22f629982cd0734_73)] | | | [removed: [70](#i6eef640963c94f0198129aab5beef55a_31)] [added: [69](#i70f957301cc34339a22f629982cd0734_73)] | | |
| [ITEM [removed: 4.](#i6eef640963c94f0198129aab5beef55a_34)] [added: 4.](#i70f957301cc34339a22f629982cd0734_76)] | | | [Mine Safety [removed: Disclosures](#i6eef640963c94f0198129aab5beef55a_34)] [added: Disclosures](#i70f957301cc34339a22f629982cd0734_76)] | | | [removed: [70](#i6eef640963c94f0198129aab5beef55a_34)] [added: [70](#i70f957301cc34339a22f629982cd0734_76)] | | |
| [ITEM [removed: 5.](#i6eef640963c94f0198129aab5beef55a_40)] [added: 5.](#i70f957301cc34339a22f629982cd0734_82)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i6eef640963c94f0198129aab5beef55a_40)] [added: Securities](#i70f957301cc34339a22f629982cd0734_82)] | | | [removed: [71](#i6eef640963c94f0198129aab5beef55a_40)] [added: [71](#i70f957301cc34339a22f629982cd0734_82)] | | |
| [ITEM [removed: 6.](#i6eef640963c94f0198129aab5beef55a_43)] [added: 6.](#i70f957301cc34339a22f629982cd0734_85)] | | | [removed: [\[Reserved\]](#i6eef640963c94f0198129aab5beef55a_43)] [added: [\[Reserved\]](#i70f957301cc34339a22f629982cd0734_85)] | | | [removed: [72](#i6eef640963c94f0198129aab5beef55a_43)] [added: [72](#i70f957301cc34339a22f629982cd0734_85)] | | |
| [ITEM [removed: 7.](#i6eef640963c94f0198129aab5beef55a_49)] [added: 7.](#i70f957301cc34339a22f629982cd0734_91)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i6eef640963c94f0198129aab5beef55a_49)] [added: Operations](#i70f957301cc34339a22f629982cd0734_91)] | | | [removed: [73](#i6eef640963c94f0198129aab5beef55a_49)] [added: [73](#i70f957301cc34339a22f629982cd0734_91)] | | |
| [ITEM [removed: 7A.](#i6eef640963c94f0198129aab5beef55a_61)] [added: 7A.](#i70f957301cc34339a22f629982cd0734_121)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#i6eef640963c94f0198129aab5beef55a_61)] [added: Risk](#i70f957301cc34339a22f629982cd0734_121)] | | | [removed: [86](#i6eef640963c94f0198129aab5beef55a_61)] [added: [84](#i70f957301cc34339a22f629982cd0734_121)] | | |
| [ITEM [removed: 8.](#i6eef640963c94f0198129aab5beef55a_64)] [added: 8.](#i70f957301cc34339a22f629982cd0734_133)] | | | [Financial Statements and Supplementary [removed: Data](#i6eef640963c94f0198129aab5beef55a_64)] [added: Data](#i70f957301cc34339a22f629982cd0734_133)] | | | [removed: [87](#i6eef640963c94f0198129aab5beef55a_64)] [added: [85](#i70f957301cc34339a22f629982cd0734_133)] | | |
| [ITEM [removed: 9.](#i6eef640963c94f0198129aab5beef55a_67)] [added: 9.](#i70f957301cc34339a22f629982cd0734_136)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i6eef640963c94f0198129aab5beef55a_67)] [added: Disclosure](#i70f957301cc34339a22f629982cd0734_136)] | | | [removed: [87](#i6eef640963c94f0198129aab5beef55a_67)] [added: [85](#i70f957301cc34339a22f629982cd0734_136)] | | |
| [ITEM [removed: 9A.](#i6eef640963c94f0198129aab5beef55a_70)] [added: 9A.](#i70f957301cc34339a22f629982cd0734_139)] | | | [Controls and [removed: Procedures](#i6eef640963c94f0198129aab5beef55a_70)] [added: Procedures](#i70f957301cc34339a22f629982cd0734_139)] | | | [removed: [88](#i6eef640963c94f0198129aab5beef55a_70)] [added: [86](#i70f957301cc34339a22f629982cd0734_139)] | | |
| [ITEM [removed: 9B.](#i6eef640963c94f0198129aab5beef55a_73)] [added: 9B.](#i70f957301cc34339a22f629982cd0734_142)] | | | [Other [removed: Information](#i6eef640963c94f0198129aab5beef55a_73)] [added: Information](#i70f957301cc34339a22f629982cd0734_142)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_73)] [added: [88](#i70f957301cc34339a22f629982cd0734_142)] | | |
| [ITEM [removed: 9C.](#i6eef640963c94f0198129aab5beef55a_76)] [added: 9C.](#i70f957301cc34339a22f629982cd0734_145)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i6eef640963c94f0198129aab5beef55a_76)] [added: Inspections](#i70f957301cc34339a22f629982cd0734_145)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_76)] [added: [88](#i70f957301cc34339a22f629982cd0734_145)] | | |
| [ITEM [removed: 10.](#i6eef640963c94f0198129aab5beef55a_82)] [added: 10.](#i70f957301cc34339a22f629982cd0734_151)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i6eef640963c94f0198129aab5beef55a_82)] [added: Governance](#i70f957301cc34339a22f629982cd0734_151)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_82)] [added: [89](#i70f957301cc34339a22f629982cd0734_151)] | | |
| [ITEM [removed: 11.](#i6eef640963c94f0198129aab5beef55a_85)] [added: 11.](#i70f957301cc34339a22f629982cd0734_154)] | | | [Executive [removed: Compensation](#i6eef640963c94f0198129aab5beef55a_85)] [added: Compensation](#i70f957301cc34339a22f629982cd0734_154)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_85)] [added: [89](#i70f957301cc34339a22f629982cd0734_154)] | | |
| [ITEM [removed: 12.](#i6eef640963c94f0198129aab5beef55a_88)] [added: 12.](#i70f957301cc34339a22f629982cd0734_157)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i6eef640963c94f0198129aab5beef55a_88)] [added: Matters](#i70f957301cc34339a22f629982cd0734_157)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_88)] [added: [89](#i70f957301cc34339a22f629982cd0734_157)] | | |
| [ITEM [removed: 13.](#i6eef640963c94f0198129aab5beef55a_91)] [added: 13.](#i70f957301cc34339a22f629982cd0734_160)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i6eef640963c94f0198129aab5beef55a_91)] [added: Independence](#i70f957301cc34339a22f629982cd0734_160)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_91)] [added: [89](#i70f957301cc34339a22f629982cd0734_160)] | | |
| [ITEM [removed: 14.](#i6eef640963c94f0198129aab5beef55a_94)] [added: 14.](#i70f957301cc34339a22f629982cd0734_163)] | | | [Principal Accountant Fees and [removed: Services](#i6eef640963c94f0198129aab5beef55a_94)] [added: Services](#i70f957301cc34339a22f629982cd0734_163)] | | | [removed: [90](#i6eef640963c94f0198129aab5beef55a_94)] [added: [89](#i70f957301cc34339a22f629982cd0734_163)] | | |
| [ITEM [removed: 15.](#i6eef640963c94f0198129aab5beef55a_100)] [added: 15.](#i70f957301cc34339a22f629982cd0734_169)] | | | [removed: [Exhibits](#i6eef640963c94f0198129aab5beef55a_100)] [added: [Exhibits](#i70f957301cc34339a22f629982cd0734_169)] and [Financial Statement [removed: Schedules](#i6eef640963c94f0198129aab5beef55a_100)] [added: Schedules](#i70f957301cc34339a22f629982cd0734_169)] | | | [removed: [91](#i6eef640963c94f0198129aab5beef55a_100)] [added: [90](#i70f957301cc34339a22f629982cd0734_169)] | | |
| [ITEM [removed: 16.](#i6eef640963c94f0198129aab5beef55a_103)] [added: 16.](#i70f957301cc34339a22f629982cd0734_172)] | | | [Form 10-K [removed: Summary](#i6eef640963c94f0198129aab5beef55a_103)] [added: Summary](#i70f957301cc34339a22f629982cd0734_172)] | | | [removed: [93](#i6eef640963c94f0198129aab5beef55a_103)] [added: [92](#i70f957301cc34339a22f629982cd0734_172)] | | |
*Except for historical financial information contained herein, the matters discussed in this [added: Annual Report on] Form 10-K may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, [added: or the Exchange Act,] and subject to the safe harbor created by the Securities Litigation Reform Act of 1995.
Such statements include declarations regarding our [removed: intent, belief, or current expectations] [added: operations, financial condition] and [removed: those of our management.][added: prospects, and business strategies, and are based on management’s current* *intent, beliefs, expectations, and assumptions.]
Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control; actual results could differ materially from those indicated [added: or implied] by such forward-looking statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under “Risk Factors”; and (iii) the other risks detailed from time-to-time in our reports and registration statements filed with the Securities and Exchange Commission, or [added: the] SEC.
Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or [removed: otherwise.*][added: otherwise.]
- We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in [removed: future] revenue.
- Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual [removed: coverage,] [added: coverage with third-party payors,] and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products.
If we are unable to [removed: secure] [added: obtain] adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.
- We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements [removed: and policy initiatives] regarding privacy, data protection, security, [removed: data access] and other matters.
Many of these laws and regulations are subject to change and uncertain [removed: or evolving guidance and] interpretation, and could result in claims, changes to our business practices, [removed: product development impacts,] monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
or

| Large accelerated filer | | | ☒ | | | | | | Accelerated filer | | | ☐ | | |
| | | | | | | | | | Emerging growth company | | | ☐ | | |
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
Shares held by persons who may be deemed affiliates have been excluded.
This determination of affiliate status with respect to the foregoing calculation is not a determination for other purposes.
| [I](#i70f957301cc34339a22f629982cd0734_3752)[TEM 1C.](#i70f957301cc34339a22f629982cd0734_3752) | | | [Cybersecurity](#i70f957301cc34339a22f629982cd0734_3752) | | | [67](#i70f957301cc34339a22f629982cd0734_3752) | | |
| | | | [Signatures](#i70f957301cc34339a22f629982cd0734_175) | | | [93](#i70f957301cc34339a22f629982cd0734_175) | | |
Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.*
| Corporate Information | | | | | | | | | | | | | | |
The mailing address of our headquarters is 6340 Sequence Drive, San Diego, California, 92121, and our telephone number at that location is (858) 200-0200.
Our website address is located at dexcom.com and our investor relations website is located at investors.dexcom.com.
We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.
We make available on our website, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
The reports are also available at www.sec.gov.
We announce material information to the public about us, our products, and other matters through a variety of means, including filings with the SEC, press releases, public conference calls, presentations, webcasts, and our investor relations website in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.
We also routinely post important information for investors on our website noted above, and we may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.
Accordingly, investors should monitor the Investor Relations portion of our website noted above.
Also available on our website are printable versions of our Audit Committee charter, Compensation Committee charter, Nominating and Governance Committee charter, Technology Committee charter, Corporate Governance Guidelines and Code of Conduct and Business Ethics.
Stockholders may request copies of these documents by mail or telephone, at the address or phone number provided above.
Except as expressly set forth in this Annual Report on Form 10-K, the contents of our website is not incorporated by reference into, or otherwise to be regarded as part of, this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website is intended to be inactive textual references only.
The information disclosed by the foregoing channels could be deemed to be material information.
As such, we encourage investors, the media, and others to follow the channels listed above and review the information disclosed through such channels.
"Dexcom", “Dexcom Clarity”, and “Dexcom One”, and other trademarks of ours appearing in this report are our property.
Other service marks, trademarks and trade names referred to in this Form 10-K are the property of their respective owners.
- We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.
| | | | | | | (Nasdaq Global Select Market) | | |
Except with respect to information specifically incorporated by reference in the Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.
| | | | [Signatures](#i6eef640963c94f0198129aab5beef55a_106) | | | [94](#i6eef640963c94f0198129aab5beef55a_106) | | |
- The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
An excerpt. Shown here: 40 of 44 rewritten, all 29 added and all 4 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2023 filing and the FY2022 filing.
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.

Item 1C. CYBERSECURITY
0 rewritten, 43 added, 0 removed, 0 unchanged
New section this year
Read the full itemFY2023 item · filed February 8, 2024
Risk Management and Strategy
We have processes in place for assessing, identifying, and managing material risks from cybersecurity threats, which are integrated into our overall enterprise risk management processes.
The processes for assessing, identifying and managing material risks from cybersecurity threats, including threats associated with our use of third-party service providers, include identifying the relevant assets that could be affected, determining possible threat sources and threat events, assessing threats based on their potential likelihood and impact, and identifying controls that are in place or necessary to manage and/or mitigate such risks.
We have established cybersecurity and privacy programs to maintain the confidentiality, integrity, availability, and privacy of protected information and ensure compliance with relevant security/privacy regulations, contractual requirements, and industry-standard frameworks.
Our cybersecurity program includes annual review and assessment by external, independent third parties, who certify and report on these programs.
For example, our Information Security Management System (ISMS) is certified as being in conformity with ISO/IEC 27001 by SRI Quality System Registrar.
We maintain cybersecurity and privacy policies and procedures in accordance with industry-standard control frameworks and applicable regulations, laws, and standards.
All corporate cybersecurity policies are reviewed and approved by senior leadership at least annually as part of our ISMS.
Our cybersecurity controls, which are the mechanisms in place to prevent, detect and mitigate threats in accordance with our policies and procedures, are based on the regulatory requirements to which we are subject and are monitored and tested both internally and externally by third parties at least annually.
These controls include regular system updates and patches, employee training on cybersecurity and privacy requirements, incident reporting, and the use of encryption to secure sensitive information.
In addition, we also regularly perform phishing tests of our employees and update our training plan at least annually.
We maintain business continuity and disaster recovery capabilities to mitigate interruptions to critical information systems and/or the loss of data and services from the effects of natural or man-made disasters to Dexcom locations.
We also provide annual privacy and security training for all employees.
Our security training incorporates awareness of cyber threats (including but not limited to malware, ransomware and social engineering attacks), password hygiene, incident reporting process, as well as physical security best practices.
In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from security incidents were immaterial.
As a result, we do not believe that risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected us, our results of operations and financial condition.
However, as discussed under “Risk Factors” in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition.
See “Risk Factors — Risks Related to Privacy and Security.” As cybersecurity threats become more frequent, sophisticated and coordinated, it is reasonably likely that we will be required to expend greater resources to continue to modify and enhance our protective measures as we pursue our strategy that includes developing and commercializing products that integrate our CGM technologies into insulin delivery systems or data platforms of our partners.
The technology integration and cloud-based depository platforms we continue to focus on can make us more vulnerable to cybersecurity threats, thereby making our pursuit of such strategies more costly.
Governance
Our Board of Directors is responsible for exercising oversight of management’s identification and management of, and planning for, risks from cybersecurity threats.
While the full Board has overall responsibility for risk oversight, the Board has delegated oversight responsibility related to risks from cybersecurity threats to the Board’s Technology Committee.
The Technology Committee reports to the Board as necessary with respect to its activities, including making such reports and recommendations to the Board and its other committees as necessary and appropriate and consistent with its purpose, described below.
The Technology Committee, comprised of independent Board members, is responsible for reviewing cybersecurity, privacy, data protection and other major technology risk exposures of the Company, the steps management has taken to monitor and control such exposures, and the Company’s compliance with applicable cybersecurity and data privacy laws and industry standards.
These reviews are provided at least quarterly.
The Technology Committee receives management updates and reports, primarily through the Company’s Cybersecurity and Privacy Committee,
a multidisciplinary team responsible for the overall governance, decision-making, risk management, awareness and compliance for cybersecurity and privacy activities across the Company.
The Cybersecurity and Privacy Committee is co-chaired by our Information Security Officer (ISO), Product Security Officer (PSO), and Chief Privacy Officer (CPO), and its members include executive officers of the Company, including our Chief Technology Officer, Chief Financial Officer, Chief Information Officer, and Chief Legal Officer, as well as representatives from the finance, internal audit, quality, regulatory, and legal teams.
Management’s role in assessing and managing the material risks from cybersecurity threats is accomplished primarily through the committee.
Members of the Cybersecurity and Privacy Committee have broad ranges of expertise and experience in information technology and security.
Our ISO, a co-chair of the committee, has over fifteen years of experience in the field of information security management, having previously led security operations and infrastructure and IT functions for a public university campus and a non-profit organization, and holds several licenses and certifications relating to information security, including a Certified Information Systems Security Manager from the Information Systems Audit and Control Association (ISACA), a Certified Information Systems Security Professional (CISSP) from the International Information Security System Security Certification Consortium (ISC2) and several technical cybersecurity certifications from the Global Information Assurance Certification (GIAC).
Our PSO, also a co-chair of the committee, has over twenty-five years of previous experience in cyber security architecture and cyber security management for a number of large Fortune 500 technology companies and holds several certifications including CISSP from the International Information Security System Security Certification Consortium , C-CISO from EC-Council, Numerous certifications from Microsoft, CISCO, Juniper, Checkpoint among others and has completed several advanced GIAC security classes from the SANS Institute.
Our ISO reports directly to our Senior Vice President, Chief Information Officer (CIO), who is a member of the committee.
He has held this role at Dexcom since 2021, having previously served as our Senior Vice President, Information Technology since 2018 and Vice President, Information Technology from 2016 to 2018.
Our CIO also has a wide range of experience within global organizations in the field of information technology, including having served in various IT leadership roles at CareFusion, a Becton Dickinson Company, from 2012 to 2016, and ResMed in San Diego from 2007 to 2012.
He holds a Bachelor of Engineering in Mechanical Engineering and a Master of Industrial Engineering.
Our PSO reports directly to our Executive Vice President, Chief Technology Officer (CTO), who is also a member of the committee.
Our CTO has held this role since 2022 and has 25 years of experience spanning consumer electronics, data storage, IoT and broadband industries.
From 2011 to 2022 he worked at Technicolor (now known as Vantiva), most recently serving as Chief Technology Officer and General Manager of the Broadband Business Division.
In addition to an MBA, he holds a Master of Science in Mechanical Engineering and a Bachelor of Mechanical Engineering.
An excerpt. Shown here: all 0 rewritten, 40 of 43 added and all 0 removed. The counts are complete. For every sentence, read Item 1C. CYBERSECURITY in the FY2023 filing.
Item 2. PROPERTIES
5 rewritten, 2 added, 2 removed, 8 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
[added: |] (1) Excludes renewals that would be at our option to extend the term of a lease expiring in 2028 for one additional three to five-year term. [added: | | | | | | | | |]
[added: |] (2) Excludes renewals that would be at our option to extend the term of a lease expiring in 2028 for four additional five-year terms and also excludes renewals that would be at our option to extend the term of a lease expiring in 2030 for two additional five-year terms. [added: | | | | | | | | |]
[added: |] (3) Represents 60-year land leases with the state authority expiring at varying dates through 2082. [added: | | | | | | | | |]
We also lease various manufacturing, administrative, warehouse and customer support real properties throughout the [removed: world including North America, Europe, and the Asia-Pacific region.][added: world.]
As of December 31, [removed: 2022,] [added: 2023,] we had approximately [removed: 46,800] [added: 65,900] square feet of laboratory space and approximately [removed: 85,200] [added: 155,700] square feet of controlled environment rooms.
In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing.
We are also expanding our facility in Mesa, Arizona to scale up manufacturing capacity.
In 2020, we commenced construction of a new facility in Malaysia that we anticipate will add substantial manufacturing capacity.
We expect to begin operations out of the new Malaysia manufacturing facility in 2023.
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
8 rewritten, 15 added, 8 removed, 13 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
There were no [added: other] unregistered sales of equity securities which have not been previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K during the [added: last three] fiscal [removed: year] [added: years] ended December 31, [removed: 2022.][added: 2023.]
On [removed: July 28, 2022, we announced that a duly authorized committee of] [added: October 24, 2023,] our Board of Directors authorized and approved a share repurchase program of up to [removed: $700] [added: $500.0] million of our outstanding common stock, with a repurchase period ending no later than [removed: June 30, 2023.][added: October 31, 2024 (“2023 Share Repurchase Program”).]
The following table provides information about purchases by [removed: the Company] [added: us] of [removed: its] [added: our] shares of common stock during the three months ended December 31, [removed: 2022:][added: 2023:]
See Note [removed: 9, “Share Repurchase Program] [added: 9 “Employee Benefit Plans] and [removed: Treasury Shares”] [added: Stockholders' Equity”] to the consolidated financial statements in Part II, Item 8 of this Annual Report [added: on Form 10-K] for [added: additional] information about [removed: purchases for] [added: our share repurchases during] the year ended December 31, [removed: 2022.][added: 2023.]
[removed: The] [added: Accordingly, the] graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the Nasdaq Composite [removed: Index and] [added: index,] the Nasdaq Medical Equipment [removed: Index] [added: index, the S&P Health Care Equipment Select Industry index, and the S&P 500 index] over the five-year period ended December 31, [removed: 2022.][added: 2023.]
The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December 31, [removed: 2017] [added: 2018] and that all dividends were reinvested.
* $100 invested on December 31, [removed: 2017] [added: 2018] in stock or index, including reinvestment of any dividends.
| | | | | | | December 31, [removed: 2017] [added: 2018] | | | | | | December 31, [removed: 2018] [added: 2019] | | | | | | December 31, [removed: 2019] [added: 2020] | | | | | | December 31, [removed: 2020] [added: 2021] | | | | | | December 31, [removed: 2021] [added: 2022] | | | | | | December 31, [removed: 2022] [added: 2023] | | |
We had approximately 35 stockholders of record as of February 1, 2024.
In connection with the accelerated share repurchase agreement with Bank of America, N.A., we issued 6,325 shares of our common stock in December 2023 in a private placement exempt from the registration requirements of the Securities Act in reliance on the exemption set forth in Section 4(a)(2) of the Securities Act.
Under the 2023 Share Repurchase Program, on October 31, 2023, we entered into an accelerated share repurchase agreement (“2023 ASR”) with Bank of America, N.A. (“BofA”) to repurchase shares of our common stock in an aggregate notional amount of up to $500.0 million.
| 10/01/2023 - 10/31/2023 | | | | | | 4,710,870 | | | | | | (1) | | | | | | 4,710,870 | | | | | | $ | 100.0 | |
| 11/01/2023 - 11/30/2023 | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 100.0 | |
| 12/01/2023 - 12/31/2023 | | | | | | — | | | | | | (1) | | | | | | — | | | | | | $ | — | |
| (1) Pursuant to the terms of the 2023 ASR, in October 2023, we paid BofA $500.0 million in cash and received an initial delivery of approximately 4.7 million shares of our common stock based on the closing market price on October 30, 2023 of $84.91. This initial delivery of shares represented approximately 80% of the notional amount of the 2023 ASR. On December 14, 2023, the 2023 ASR was settled. Based on the volume-weighted average price of our common stock, less a discount, of $106.28 during the term of the 2023 ASR, we owed BofA 6,325 shares of common stock. We elected to settle the forward contract by issuing 6,325 treasury shares on December 15, 2023 to BofA. | | | | | | | | | | | | | | | | | | | | | | | | | | |
Our 2022 Annual Report on Form 10-K included a comparison of the 5-year cumulative total return of our common stock with the Nasdaq Composite index and the Nasdaq Medical Equipment index.
As a result of the discontinuation of the Nasdaq Medical Equipment index in 2022, we believe that the S&P Health Care Equipment Select Industry index is a more appropriate index for comparison of our stock performance.

| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 182.59 | | | | | $ | 308.61 | | | | | $ | 448.21 | | | | | $ | 378.10 | | | | | $ | 414.32 | |
| S&P 500 | | | | | | $ | 100.00 | | | | | $ | 131.49 | | | | | $ | 155.68 | | | | | $ | 200.37 | | | | | $ | 164.08 | | | | | $ | 207.21 | |
| S&P Health Care Equipment | | | | | | $ | 100.00 | | | | | $ | 122.72 | | | | | $ | 163.40 | | | | | $ | 169.11 | | | | | $ | 129.60 | | | | | $ | 122.26 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 136.69 | | | | | $ | 198.10 | | | | | $ | 242.03 | | | | | $ | 163.28 | | | | | $ | 236.17 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 97.52 | | | | | $ | 136.07 | | | | | $ | 140.62 | | | | | $ | 94.93 | | | | | | | |
We had fewer than 40 stockholders of record as of December 31, 2022.
As of December 31, 2022, approximately $142.3 million remained available for repurchase pursuant to our share repurchase program.
| 10/01/2022 - 10/31/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | $ | 142.3 | |
| 11/01/2022 - 11/30/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | $ | 142.3 | |
| 12/01/2022 - 12/31/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | $ | 142.3 | |
| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 208.75 | | | | | $ | 381.15 | | | | | $ | 644.22 | | | | | $ | 935.62 | | | | | $ | 789.27 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 97.16 | | | | | $ | 132.81 | | | | | $ | 192.47 | | | | | $ | 235.15 | | | | | $ | 158.65 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 62.72 | | | | | $ | 61.17 | | | | | $ | 85.34 | | | | | $ | 88.20 | | | | | $ | 59.54 | |
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
1 rewritten, 0 added, 0 removed, 2 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
The information required is set forth under “Report of Independent Registered Public Accounting Firm,” “Consolidated Balance Sheets,” “Consolidated Statements of Operations,” “ Consolidated Statements of Comprehensive Income,” “Consolidated Statements of Stockholders’ Equity,” “Consolidated Statements of Cash Flows” and “Notes to Consolidated Financial Statements” on pages [removed: [F-10](#i6eef640963c94f0198129aab5beef55a_130)] [added: [F-10](#i70f957301cc34339a22f629982cd0734_199)] to [removed: [F-44](#i6eef640963c94f0198129aab5beef55a_199)] [added: [F-4](#i70f957301cc34339a22f629982cd0734_370)[3](#i70f957301cc34339a22f629982cd0734_370)] of this Annual Report and is incorporated into this Item 8 by reference.
Item 9A. CONTROLS AND PROCEDURES
11 rewritten, 1 added, 1 removed, 32 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
Regulations under the [removed: Securities] Exchange [removed: Act of 1934] [added: Act,] require public companies to maintain “disclosure controls and procedures,” which are defined to mean a company’s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the [removed: Securities] Exchange [removed: Act of 1934] [added: Act,] is accumulated and timely communicated to management, including our Chief Executive Officer and Chief Financial Officer, recorded, processed, summarized, and reported within the time periods specified in the [removed: Securities and Exchange Commission’s] [added: SEC’s] rules and forms.
Based on their evaluation as of December 31, [removed: 2022,] [added: 2023,] our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date for this purpose.
There were no changes in our internal control over financial reporting during our last fiscal quarter that have materially affected, or are reasonably likely to materially [removed: affect] [added: affect,] our internal control over financial reporting.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the [removed: Securities] Exchange [removed: Act of 1934.][added: Act.]
Our management, with the participation of the Chief Executive and Chief Financial Officers, assessed the effectiveness of our internal control over financial reporting as of December 31, [removed: 2022.][added: 2023.]
Based on this assessment, our management, with the participation of the Chief Executive and Chief Financial Officers, believes that, as of December 31, [removed: 2022,] [added: 2023,] our internal control over financial reporting is effective based on those criteria.
The effectiveness of our internal control over financial reporting as of December 31, [removed: 2022] [added: 2023] has been audited by Ernst & Young [removed: LLP] [added: LLP,] an Independent Registered Public Accounting Firm, as stated in their report which is included herein.
[removed: The] [added: To the Stockholders and the] Board of Directors [removed: and Stockholders] of DexCom, Inc.
We have audited DexCom, Inc.’s internal control over financial reporting as of December 31, [removed: 2022,] [added: 2023,] based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 [removed: Framework)] [added: framework)] (the COSO criteria).
In our opinion, DexCom, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2022,] [added: 2023,] based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of DexCom, Inc. as of December 31, [removed: 2022] [added: 2023] and [removed: 2021,] [added: 2022,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2022,] [added: 2023,] and the related notes and financial statement schedule listed in the Index at Item 15(a) and our report dated February [removed: 9, 2023] [added: 8, 2024] expressed an unqualified opinion thereon.
February 8, 2024
February 9, 2023
Item 9B. OTHER INFORMATION
0 rewritten, 17 added, 1 removed, 0 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
Trading Plans
During the three months ended December 31, 2023, the following Section 16 officers and directors adopted or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act):
| Name | | | Title | | | Action | | | Action Date | | | Aggregate Number of Shares to be Sold(1) | | | Expiration Date(2) | | |
| Matthew Dolan | | | Executive Vice President, Strategy, Corporate Development and Dexcom Labs | | | Adoption | | | 12/15/2023 | | | 15,326 | | | 12/15/2024 | | |
| Paul Flynn | | | Executive Vice President, Global Revenue | | | Adoption | | | 12/15/2023 | | | 31,253 | | | 12/15/2024 | | |
| Girish Naganathan | | | Executive Vice President, Chief Technology Officer | | | Adoption | | | 11/20/2023 | | | 5,137 | | | 11/20/2024 | | |
| Steven R. Pacelli | | | Executive Vice President and Managing Director, Dexcom Ventures | | | Adoption | | | 11/27/2023 | | | 15,000 | | | 1/23/2025 | | |
| Barry J. Regan | | | Executive Vice President, Global Operations | | | Adoption | | | 12/4/2023 | | | 28,430 | | | 12/4/2024 | | |
| Kevin R. Sayer | | | Chairperson, President and Chief Executive Officer | | | Adoption | | | 12/12/2023 | | | 100,965 | | | 12/12/2024 | | |
| Sadie M. Stern | | | Executive Vice President, Chief Human Resources Officer | | | Adoption(3) | | | 12/12/2023 | | | 12,825 | | | 3/11/2025 | | |
| Sadie M. Stern | | | Executive Vice President, Chief Human Resources Officer | | | Termination(3) | | | 12/12/2023 | | | 4,708 | | | 3/8/2024 | | |
| Jereme M. Sylvain | | | Executive Vice President, Chief Financial Officer | | | Adoption | | | 11/21/2023 | | | 6,863 | | | 11/21/2024 | | |
| (1) The actual number of shares sold may depend on the net shares vested as a result of tax withholding obligations, the vesting of certain performance-based stock units, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time. | | | | | | | | | | | | | | | | | |
| (2) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the date listed in the table. | | | | | | | | | | | | | | | | | |
| (3) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 12, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act. | | | | | | | | | | | | | | | | | |
Each of the Rule 10b5-1 trading arrangements that were adopted in the above table are in accordance with our insider trading policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.
No Section 16 officers or directors adopted, modified, or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) during the three months ended December 31, 2023.
None.
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
2 rewritten, 2 added, 0 removed, 5 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
This code of ethics, titled the “Code of Conduct and [removed: Ethics for Chief Executive Officer and Senior Finance Personnel,”] [added: Business Ethics,”] is publicly available on our Internet website at https://dexcom.gcs-web.com/corporate-governance.
The information concerning the Audit Committee of the Board of Directors required by this Item is incorporated by reference to [removed: information set forth in] the [added: section of the] Proxy [removed: Statement.][added: Statement entitled “Committees of the Board and Meetings - Audit Committee.”]
When required by the rules of Nasdaq, or the SEC, we will disclose any future amendment to, or waiver of, any provision of the code of ethics for our principal executive officer and principal financial officer or any member or members of our board of directors on our website within four business days following the date of such amendment or waiver.
The information concerning the Company’s insider trading policies and compliance with Section 16(a) required by this Item is incorporated by reference to the sections of the Proxy Statement entitled “Insider Trading Policy” and Delinquent Section 16(a) Reports, respectively.
Item 11. EXECUTIVE COMPENSATION
0 rewritten, 1 added, 1 removed, 0 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
The information required by this Item concerning executive compensation and our Compensation Committee is incorporated by reference to the sections in the Proxy Statement entitled “Compensation Discussion and Analysis,” “2023 Summary Compensation Table,” “Grants of Plan-Based Awards,” “Outstanding Equity Awards at December 31, 2023,” “2023 Option Awards Exercises and Stock Vested,” “Executive Nonqualified Deferred Compensation Plan,” “Employment, Severance and Change in Control Arrangements,” “2023 Director Compensation,” “Risks from Compensation Policies and Practices,” “Chief Executive Officer Pay Ratio,” “Compensation Committee Interlocks,” and “Compensation Committee Report.”
The information required by this Item concerning executive compensation and our Compensation Committee is incorporated by reference to information set forth in the Proxy Statement under the heading “Executive Compensation.”
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
1 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
The information required by this Item is incorporated by reference to [removed: information set forth] [added: the sections] in the Proxy Statement [removed: under the headings “Principal Stockholders and Stock] [added: entitled “Security] Ownership [removed: by] [added: of Certain Beneficial Owners and] Management” and “Equity Compensation Plan Information.”
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
2 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
The information required by this Item with respect to director independence is incorporated by reference to [removed: information set forth] [added: the section] in the Proxy [removed: Statement.][added: Statement entitled “Corporate Governance - Director Independence”.]
The information concerning certain relationships and related transactions required by this Item is incorporated by reference to the section in the Proxy Statement entitled “Certain [removed: Transactions.”][added: Transactions With Related Persons.”]
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
The information concerning principal accountant fees and services required by this Item is incorporated by reference to the section in the Proxy Statement entitled “Ratification of [removed: Selection of] Independent Registered Public Accounting Firm.”
Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
24 rewritten, 7 added, 10 removed, 21 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
| [removed: [3.01](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex31.htm)] [added: [3.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm)[2](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm)] | | | | | | [removed: [Restated Certificate of Incorporation] [added: [Amended and Restated Bylaws] of [removed: Dexcom, Inc.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex31.htm)] [added: DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 21, 2021 | | | | | | [removed: 3.1] [added: 3.3] | | | | | | | | | | | |
| [removed: [4.01](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] [added: [4.](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)[1](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] | | | | | | [Form of Specimen Certificate [removed: for Registrant’s common] [added: for](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) [DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) [common] stock.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm) | | | | | | S-1/A | | | | | | 333-122454 | | | | | | March 24, 2005 | | | | | | 4.01 | | | | | | | | | | | |
| [removed: [4.02](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] [added: [4.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)[2](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] | | | | | | [Indenture, dated [removed: as of] November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2023).](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | December 3, 2018 | | | | | | 4.1 | | | | | | | | | | | |
| [removed: [4.03](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] [added: [4.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)[3](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] | | | | | | [Indenture, dated [removed: as of] May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due 2025).](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 15, 2020 | | | | | | 4.1 | | | | | | | | | | | |
| [removed: [4.04](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex404securitie.htm)] [added: [4.5](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex45-securitie.htm)] | | | | | | [Description of Securities Registered Under Section 12 of the Exchange [removed: Act.](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex404securitie.htm)] [added: Act.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex45-securitie.htm)] | | | | | | [removed: 10-K] | | | | | | [removed: 000-51222] | | | | | | [removed: February 11, 2021] | | | | | | [removed: 4.04] | | | | | | [added: X] | | | | | |
| [removed: [10.01](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: [10.1*](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] | | | | | | [Offer letter between DexCom, Inc. and Kevin [removed: Sayer] [added: Sayer,] dated May 3, [removed: 2011.*](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: 2011.](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 3, 2011 | | | | | | 10.28 | | | | | | | | | | | |
| [removed: [10.02](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] [added: [10.2](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] | | | | | | [Sublease between DexCom, Inc. and Entropic Communications, [removed: LLC dated] [added: LLC](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)[,](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm) [dated] February 1, 2016.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | April 27, 2016 | | | | | | 10.36 | | | | | | | | | | | |
| [removed: [10.04](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: [10.3*](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] | | | | | | [removed: [Executive] [added: [DexCom, Inc. Executive] Deferred Compensation [removed: Plan.*](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: Plan.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 4, 2019 | | | | | | 10.02 | | | | | | | | | | | |
| [removed: [10.05](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] [added: [10.4](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | [Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, [removed: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] [added: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.40 | | | | | | | | | | | |
| [removed: [10.06](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] [added: [10.5*](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] | | | | | | [Form of Indemnity Agreement between [removed: Registrant] [added: DexCom, Inc.] and each of its directors and executive [removed: officers.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] [added: officers.](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 11, 2021 | | | | | | 10.43 | | | | | | | | | | | |
| [removed: [10.07](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] [added: [10.6*](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] | | | | | | [removed: [DexCom] [added: [DexCom, Inc.] Incentive Bonus [removed: Plan.*](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] [added: Plan.](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | March 17, 2021 | | | | | | 10.1 | | | | | | | | | | | |
| [removed: [10.08](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] [added: [10.7](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] | | | | | | [Second Amended and Restated Credit Agreement dated October 13, 2021 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | 10.39 | | | | | | | | | | | |
| [removed: [10.09](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm)] [added: [10.8](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm)] | | | | | | [Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P., as amended on August 18, 2010 and October 1, 2014.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm) | | | | | | [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 9, 2023] | | | | | | [added: 10.09] | | | | | | [removed: X] | | | | | |
| [removed: [10.15](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1015-amendme.htm)] [added: [10.14](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1014-amended.htm)] | | | | | | [removed: [Amendment No. 1 to] [added: [Amended and Restated] Collaboration and License [removed: Agreement] [added: Agreement,] dated [removed: October 25, 2016] [added: November 20, 2018,] by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences [removed: LLC), as amended on November 20, 2018.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1015-amendme.htm)] [added: LLC).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1014-amended.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [10.17](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1017-amended.htm)] [added: [10.13*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1013-amended.htm)] | | | | | | [Amended and Restated 2015 Equity Incentive Plan and forms of award [removed: agreements.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1017-amended.htm)] [added: agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1013-amended.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [10.18](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] [added: [10.9](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] | | | | | | [Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019, as amended on October 21, [removed: 2019 and] [added: 2019,] May 25, 2021, and December 23, [removed: 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] [added: 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] | | | | | | [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 9, 2023] | | | | | | [added: 10.18] | | | | | | [removed: X] | | | | | |
| [removed: [10.19](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm)] [added: [10.12*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1012-2015emp.htm)] | | | | | | [2015 Employee Stock Purchase [removed: Plan, amended on December 13, 2019] [added: Plan] and [removed: form] [added: forms] of subscription [removed: agreement.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm)] [added: agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1012-2015emp.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [21.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2101_12312022.htm)] [added: [21.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2101_12312023.htm)] | | | | | | [List of [removed: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2101_12312022.htm)] [added: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2101_12312023.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [23.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2301_12312022.htm)] [added: [23.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2301_12312023.htm)] | | | | | | [Consent of Independent Registered Public Accounting [removed: Firm.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2301_12312022.htm)] [added: Firm.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex2301_12312023.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [31.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3101.htm)] [added: [31.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3101.htm)] | | | | | | [Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3101.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3101.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [31.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3102.htm)] [added: [31.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3102.htm)] | | | | | | [Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3102.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3102.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [32.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3201.htm)] [added: [32.01*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3201.htm)] | | | | | | [Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3201.htm)] [added: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3201.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [32.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3202.htm)] [added: [32.02*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3202.htm)] | | | | | | [Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3202.htm)] [added: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023exhibit3202.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: —] [added: 104] | | | | | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
[Schedule II – Valuation and Qualifying Accounts](#i70f957301cc34339a22f629982cd0734_376).
| [3.](https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm)[1](https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm) | | | | | | [Restated Certificate of Incorporation of DexCom, Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 10, 2022 | | | | | | 3.1 | | | | | | | | | | | |
| [4.4](https://www.sec.gov/Archives/edgar/data/1093557/000119312523137248/d300995dex41.htm) | | | | | | [Indenture, dated May 5, 2023, between DexCom, Inc. and U.S. Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028).](https://www.sec.gov/Archives/edgar/data/1093557/000119312523137248/d300995dex41.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 5, 2023 | | | | | | 4.1 | | | | | | | | | | | |
| [10.10](https://www.sec.gov/Archives/edgar/data/1093557/000119312523149463/d446905dex101.htm)[*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm) | | | | | | [DexCom, Inc. Amended and Restated Severance and Change in Control Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000119312523149463/d446905dex101.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 19, 2023 | | | | | | 10.1 | | | | | | | | | | | |
| [10.11](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000174/dxcm6302023ex1006-firstame.htm) | | | | | | [First Amendment to Second Amended and Restated Credit Agreement, dated June 1, 2023 by and between DexCom, Inc. and JPMorgan Chase Bank National Association.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000174/dxcm6302023ex1006-firstame.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | July 27, 2023 | | | | | | 10.06 | | | | | | | | | | | |
| [19.1*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) | | | | | | [Procedures and Guidelines](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm)[Governing](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm)[Securities Trades by Company Personnel](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm)[.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex191-procedur.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [97.1*](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex971-compensa.htm) | | | | | | [Compensation Recovery Policy.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex971-compensa.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
For the three fiscal years ended December 31, 2022, Schedule II – Valuation and Qualifying Accounts.
| [3.02](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm) | | | | | | [Amended and Restated Bylaws of DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 21, 2021 | | | | | | 3.3 | | | | | | | | | | | |
| [10.03](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm) | | | | | | [Industrial Net Lease, Broadway dated April 28, 2016, by and between PRA/LB, L.L.C. and DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 2, 2016 | | | | | | 10.39 | | | | | | | | | | | |
| [10.10](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1010-amendme.htm) | | | | | | [Amendment Number One to Non-Exclusive Distribution Agreement, between RGH Enterprises, Inc. and DexCom, Inc., dated March 29, 2011, as amended on March 28, 2013, December 4, 2013, and April 30, 2016.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1010-amendme.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.11](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1011-adapthe.htm) | | | | | | [Amended and Restated Non-Exclusive Distribution Agreement with Diabetes Management and Supplies, LLC, dated August 10, 2015, as amended on April 7, 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1011-adapthe.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.12](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1012-distrib.htm) | | | | | | [Distribution Services Agreement dated November 7, 2015 between DexCom, Inc. and AmerisourceBergen Drug Corporation, as amended on November 1, 2018 and December 2, 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1012-distrib.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.13](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1013-amended.htm) | | | | | | [Amended and Restated Non-Exclusive Distribution Agreement with Byram Healthcare dated February 1, 2016.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1013-amended.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.14](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm) | | | | | | [Standard Form of Agreement dated May 2, 2016, by and between DexCom, Inc. and Skanska USA Building Inc. and](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm) [Standard Form of Agreement dated](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm)[May 1, 2017, by and between DexCom, Inc. and Skanska USA Building Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.16](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1016-severan.htm) | | | | | | [Severance and Change in Control Plan and form of participation agreement.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1016-severan.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.20](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1020-officel.htm) | | | | | | [Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated January 31, 2020, as amended on November 17, 2020, and forms of certificates.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1020-officel.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
Item 16. FORM 10-K SUMMARY
488 rewritten, 160 added, 247 removed, 666 unchanged
Read the full itemFY2023 item · filed February 8, 2024FY2022 item · filed February 9, 2023
| Dated: February [removed: 9, 2023] [added: 8, 2024] | | | | | | | | | | | | By: | | | | | | /s/ JEREME M. SYLVAIN | | |
Sylvain, jointly and severally, his [added: or her] attorneys-in-fact, each with the power of substitution, for him [added: or her] in any and all capacities, to sign any amendments to this [added: Annual] Report on Form 10-K and to file same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, [added: granting unto each of said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person,] hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.
| /s/ KEVIN R. SAYER | | | | | | Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ JEREME M. SYLVAIN | | | | | | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ MARK G. FOLETTA | | | | | | Lead Independent Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ STEVEN R. ALTMAN | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ NICHOLAS AUGUSTINOS | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ RICHARD A. COLLINS | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ KAREN DAHUT | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ BRIDGETTE P. HELLER | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ BARBARA E. KAHN | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ KYLE MALADY | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| /s/ ERIC J. TOPOL | | | | | | Director | | | | | | February [removed: 9, 2023] [added: 8, 2024] | | |
| [Report of Independent Registered Public [removed: A](#i6eef640963c94f0198129aab5beef55a_112)[ccounting Firm](#i6eef640963c94f0198129aab5beef55a_112)] [added: Accounting Firm](#i70f957301cc34339a22f629982cd0734_181)] | | | [removed: F-[2](#i6eef640963c94f0198129aab5beef55a_112)] [added: F-[2](#i70f957301cc34339a22f629982cd0734_181)] | | |
| [Consolidated Balance [removed: Sheets](#i6eef640963c94f0198129aab5beef55a_115)] [added: Sheets](#i70f957301cc34339a22f629982cd0734_184)] | | | [removed: F-[4](#i6eef640963c94f0198129aab5beef55a_115)] [added: F-[4](#i70f957301cc34339a22f629982cd0734_184)] | | |
| [Consolidated Statements of [removed: Operations](#i6eef640963c94f0198129aab5beef55a_118)] [added: Operations](#i70f957301cc34339a22f629982cd0734_187)] | | | [removed: F-[5](#i6eef640963c94f0198129aab5beef55a_118)] [added: F-[5](#i70f957301cc34339a22f629982cd0734_187)] | | |
| [Consolidated Statements of Comprehensive [removed: Income](#i6eef640963c94f0198129aab5beef55a_121)] [added: Income](#i70f957301cc34339a22f629982cd0734_190)] | | | [removed: F-[6](#i6eef640963c94f0198129aab5beef55a_121)] [added: F-[6](#i70f957301cc34339a22f629982cd0734_190)] | | |
| [Consolidated Statements of Stockholders’ [removed: Equity](#i6eef640963c94f0198129aab5beef55a_124)] [added: Equity](#i70f957301cc34339a22f629982cd0734_193)] | | | [removed: F-[7](#i6eef640963c94f0198129aab5beef55a_124)] [added: F-[7](#i70f957301cc34339a22f629982cd0734_193)] | | |
| [Consolidated Statements of Cash [removed: Flows](#i6eef640963c94f0198129aab5beef55a_127)] [added: Flows](#i70f957301cc34339a22f629982cd0734_196)] | | | [removed: F-[8](#i6eef640963c94f0198129aab5beef55a_127)] [added: F-[8](#i70f957301cc34339a22f629982cd0734_196)] | | |
| [Notes to Consolidated Financial [removed: Statements](#i6eef640963c94f0198129aab5beef55a_130)] [added: Statements](#i70f957301cc34339a22f629982cd0734_199)] | | | [removed: F-[10](#i6eef640963c94f0198129aab5beef55a_130)] [added: F-[10](#i70f957301cc34339a22f629982cd0734_199)] | | |
[removed: The] [added: To the Stockholders and the] Board of Directors [removed: and Stockholders] of DexCom, Inc.
We have audited the accompanying consolidated balance sheets of DexCom, Inc. (the Company) as of December 31, [removed: 2022] [added: 2023] and [removed: 2021,] [added: 2022,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2022,] [added: 2023,] and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, [removed: 2022] [added: 2023] and [removed: 2021,] [added: 2022,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2022,] [added: 2023,] in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2022,] [added: 2023,] based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 [removed: Framework)] [added: framework)] and our report dated February [removed: 9, 2023] [added: 8, 2024] expressed an unqualified opinion thereon.
| | | | [removed: | | |] Auditing management’s determination of [removed: transaction price including] variable consideration [added: relating to pharmacy rebates] involved a high degree of subjectivity in evaluating management’s estimates. In estimating pharmacy rebates, management applies contracted rates to estimates of products sold subject to rebate, known market events or trends and channel inventory data. | | | [added: | | |]
| | | | [removed: | | |] Our audit procedures also included, among others, evaluating the significant assumptions and the accuracy and completeness of the underlying data used in management’s calculations. This included testing contractual rates, management’s estimates of products sold subject to rebate, and inventory held by third parties at the end of the period, through a combination of underlying data validation by inspection of source documents, agreement to underlying contracts, [added: and] review for consistency against historical [removed: data, and review of trending of inventory held at third parties versus inventory sold into the channel.] [added: data.] In addition, we inspected the results of the Company’s [removed: retrospective review] analysis of pharmacy rebates claimed and evaluated the estimates made based on historical experience. | | | [added: | | |]
| [removed: 2022] | | | [added: 2023] | | | [removed: 2021] | | | [added: 2022] | | | [added: | | | 2021 | | |]
| *(In millions, except par value data)* | | | | | | | | | [removed: (As Adjusted)*] | | |
| Cash and cash equivalents | | | $ | [added: 566.3 | | | | | $ |] 642.3 | | | | | $ | 1,052.6 | |
| Short-term marketable securities | | | [removed: 1,813.9] [added: 2,157.8] | | | | | | [removed: 1,678.6] [added: 1,813.9] | | |
| Accounts receivable, net | | | [removed: 713.3] [added: 973.9] | | | | | | [removed: 514.3] [added: 713.3] | | |
| Inventory | | | [removed: 306.7] [added: 559.6] | | | | | | [removed: 357.3] [added: 306.7] | | |
| Prepaid and other current assets | | | [removed: 192.6] [added: 168.3] | | | | | | [removed: 81.6] [added: 192.6] | | |
| Total current assets | | | [removed: 3,668.8] [added: 4,425.9] | | | | | | [removed: 3,684.4] [added: 3,668.8] | | |
| Property and equipment, net | | | [removed: 1,055.6] [added: 1,113.1] | | | | | | [removed: 801.8] [added: 1,055.6] | | |
| Operating lease right-of-use assets | | | [removed: 80.0] [added: 71.4] | | | | | | [removed: 88.1] [added: 80.0] | | |
| Goodwill | | | [removed: 25.7] [added: 25.2] | | | | | | [removed: 26.5] [added: 25.7] | | |
| Intangibles, net | | | [removed: 173.3] [added: 134.5] | | | | | | [removed: 31.5] [added: 173.3] | | |
| Deferred tax assets | | | [removed: 341.2] [added: 419.4] | | | | | | [removed: 290.5] [added: 341.2] | | |
| Other assets | | | [removed: 47.1] [added: 75.0] | | | | | | [removed: 10.5] [added: 47.1] | | |
| /s/ RIMMA DRISCOLL | | | | | | Director | | | | | | February 8, 2024 | | |
| Rimma Driscoll | | | | | | | | | | | | | | |
February 8, 2024
| 2023 | | | | | | 2022 | | | | | |
| Other income (expense), net | | | 112.7 | | | | | | (0.4) | | | | | | (9.0) | | |
| Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs | | | | | | 3.7 | | | | | | — | | | | | | (323.4) | | | | | | — | | | | | | — | | | | | | 323.2 | | | | | | (0.2) | | |
| Purchases of treasury stock, including excise tax | | | | | | (6.3) | | | | | | — | | | | | | (0.2) | | | | | | — | | | | | | — | | | | | | (689.0) | | | | | | (689.2) | | |
| Conversions of 2023 Notes | | | | | | 12.2 | | | | | | — | | | | | | (13.1) | | | | | | — | | | | | | — | | | | | | — | | | | | | (13.1) | | |
| Benefit of note hedge upon conversions of 2023 Notes | | | | | | (12.2) | | | | | | — | | | | | | 1,496.5 | | | | | | — | | | | | | — | | | | | | (1,490.3) | | | | | | 6.2 | | |
| Purchase of capped call transactions, net of tax | | | | | | — | | | | | | — | | | | | | (76.3) | | | | | | — | | | | | | — | | | | | | — | | | | | | (76.3) | | |
| Balance at December 31, 2023 | | | | | | 385.4 | | | | | | $ | 0.4 | | | | | $ | 3,514.6 | | | | | $ | (16.7) | | | | | $ | 1,021.4 | | | | | $ | (2,451.1) | | | | | $ | 2,068.6 | |
| Deferred income taxes | | | (55.0) | | | | | | (21.6) | | | | | | 15.8 | | |
| Purchases of capped call transactions | | | (101.3) | | | | | | — | | | | | | — | | |
| Payments for conversions of senior convertible notes | | | (787.3) | | | | | | — | | | | | | — | | |
| December 31, 2023 | | | | | | | | | | | | | | |
For finance leases, lease expense is recognized as interest and depreciation; interest using the effective interest method and depreciation on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term.
Short-term leases with lease terms of 12 months or less are not recorded on the balance sheet and are recognized on a straight line basis over the lease term.
Our lease agreements may contain lease components and non-lease components.
For certain asset classes, we have elected to account for both of those components as a single lease component.
We use a portfolio approach to account for the right-of-use assets and liabilities associated with certain machinery and equipment leases.
Variable lease payments are recognized in the period in which the obligation for those payments are incurred.
| Collaborative sales-based milestones | | | | | | 0.7 | | | | | | — | | | | | | — | | |
We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.
In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*.
The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets.
The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources.
All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment.
We are currently evaluating the impact of this standard on our consolidated financial statements and disclosures.
In December 2023, the FASB issued ASU 2023-09, *Improvements to Income Tax Disclosures*.
The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid.
The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions.
The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted.
The ASU should be applied on a prospective basis although retrospective application is permitted.
We are currently evaluating the impact of this standard on our consolidated financial disclosures.
In the fourth quarter of 2023, we issued 3.7 million shares of our common stock in connection with our achievement of the first sales-based milestone.
See the effective tax rate reconciliation in Note 8 “Income Taxes” to the consolidated financial statements for more information on the tax benefits related to the collaboration agreement milestone share-based payments for the periods presented.
| Cash equivalents | | | $ | 315.9 | | | | | $ | — | | | | | $ | — | | | | | $ | 315.9 | |
There were no significant impairment losses during the twelve months ended December 31, 2021.
| | | | December 31, 2023 | | | | | | | | | | | | | | | | | | | | |
| U.S. government agencies (1) | | | $ | 1,611.8 | | | | | $ | 1.2 | | | | | $ | (0.5) | | | | | $ | 1,612.5 | |
| /s/ JAY S. SKYLER | | | | | | Director | | | | | | February 9, 2023 | | |
| Jay S. Skyler, M.D. | | | | | | | | | | | | | | |
February 9, 2023
| * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | |
| Amortization of intangible assets | | | 7.5 | | | | | | 3.7 | | | | | | 2.5 | | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2019 (As Adjusted)* | | | | | | 366.4 | | | | | | $ | 0.4 | | | | | $ | 1,675.6 | | | | | $ | 2.3 | | | | | $ | (695.7) | | | | | $ | (100.0) | | | | | $ | 882.6 | |
| ASU 2020-06 Convertible Debt Full Retrospective Adoption | | | | | | — | | | | | | — | | | | | | (242.3) | | | | | | — | | | | | | 67.8 | | | | | | — | | | | | | (174.5) | | |
| Repurchase and conversions of 2022 Notes | | | | | | 13.5 | | | | | | — | | | | | | 112.9 | | | | | | — | | | | | | — | | | | | | — | | | | | | 112.9 | | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis on January 1, 2020. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Deferred income taxes (including benefit from valuation allowance release) | | | (21.6) | | | | | | 15.8 | | | | | | (260.5) | | |
| Repurchase of convertible notes | | | — | | | | | | — | | | | | | (282.6) | | |
| | | | | | | | | | (As Adjusted)* | | | | | | (As Adjusted)* | | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | |
Amortization expense related to intangible assets has been presented separately from selling, general and administrative expenses in our consolidated statement of operations.
| Stock Split | | | | | | | | | | | | | | |
On June 10, 2022, the Company effected a four-for-one forward stock split of its common stock to shareholders of record as of May 19, 2022.
The par value of the common stock remains $0.001 per share.
All share and per share information has been retroactively adjusted to reflect the stock split for all periods presented.
the model, such as interest rates and volatility, can be corroborated by readily observable market data for substantially the full term of the assets or liabilities.
maximize liquidity.
The change in goodwill for the twelve months ended December 31, 2021 consisted of goodwill we recorded for acquisitions that were not significant, individually or in the aggregate, and translation adjustments on our foreign currency denominated goodwill.
We also provide free-of-charge software, mobile applications and updates for our Dexcom Share® remote monitoring system.
The standalone selling prices of Dexcom Share® are estimated based on an expected cost plus a margin approach.
long-term liabilities in our consolidated balance sheets.
In August 2020, the FASB issued ASU 2020-06, which simplifies the accounting for convertible debt instruments, amends the guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share calculations.
We previously followed in Accounting Standard Codification, or ASC, 470-20, which required us to separate each of our convertible debt instruments at issuance into two units of accounting, a liability component, based on our nonconvertible debt borrowing rate at issuance, and an equity component.
Under ASU 2020-06, we now account for each of our convertible debt instruments as a single unit of accounting, a liability, because we concluded that there were no material conversion features that require bifurcation as a derivative under ASC 815-15 and our convertible debt instruments were not issued at a substantial premium.
Since we adopted ASU 2020-06 using the full retrospective approach, we were required to apply the guidance to all convertible debt instruments we had outstanding as of January 1, 2020.
Upon adoption of ASU 2020-06 as of January 1, 2020, we recognized $67.8 million cumulative-effect adjustment to increase retained earnings for the decrease in interest expense and $242.3 million decrease in additional paid in capital for the elimination of the equity component.
We have updated these financial statements to reflect the cumulative adjustment for the periods presented.
We have labeled our prior period financial statements and related notes “As Adjusted” to indicate the change required under the new accounting guidance.
Below is a summary of the changes in our consolidated balance sheets we originally reported as of December 31, 2020 and 2021 under the ASC 470-20 legacy guidance compared to our adjusted consolidated balance sheets under the new ASU 2020-06 guidance we adopted and reflective of our four-for-one forward stock split:
| Consolidated Balance Sheet | | | As of December 31, 2020 | | | | | | | | | | | | | | | | | | | | |
| *(In millions)* | | | As Previously Reported | | | | | | ASU 2020-06 Adjustment | | | | | | Stock Split Adjustment | | | | | | As Adjusted | | |
| Deferred tax assets | | | $ | 216.4 | | | | | $ | 91.3 | | | | | $ | — | | | | | $ | 307.7 | |
| Long-term senior convertible notes | | | 1,667.2 | | | | | | 365.9 | | | | | | — | | | | | | 2,033.1 | | |
| Common stock | | | 0.1 | | | | | | — | | | | | | 0.3 | | | | | | 0.4 | | |
| Additional paid-in-capital | | | 2,125.3 | | | | | | (398.5) | | | | | | (0.3) | | | | | | 1,726.5 | | |
An excerpt. Shown here: 40 of 488 rewritten, 40 of 160 added and 40 of 247 removed. The counts are complete. For every sentence, read Item 16. FORM 10-K SUMMARY in the FY2023 filing and the FY2022 filing.